<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Blood pressure lowering efficacy of renin inhibitors for primary hypertension - Musini, VM - 2017 | Cochrane Library</title> <meta content="Blood pressure lowering efficacy of renin inhibitors for primary hypertension - Musini, VM - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007066.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Blood pressure lowering efficacy of renin inhibitors for primary hypertension - Musini, VM - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007066.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007066.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Blood pressure lowering efficacy of renin inhibitors for primary hypertension" name="citation_title"/> <meta content="Vijaya M Musini" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="vijaya@ti.ubc.ca" name="citation_author_email"/> <meta content="Kendra AK Lawrence" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Patricia M Fortin" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Ken Bassett" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="James M Wright" name="citation_author"/> <meta content="University of British Columbia" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD007066.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/04/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007066.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007066.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007066.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amides [administration &amp; dosage, adverse effects, *therapeutic use]; Antihypertensive Agents [administration &amp; dosage, adverse effects, *therapeutic use]; Blood Pressure [*drug effects]; Diarrhea [chemically induced]; Fumarates [administration &amp; dosage, adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Renin [*antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007066.pub3&amp;doi=10.1002/14651858.CD007066.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007066\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007066\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","ms","ja","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007066.pub3",title:"Blood pressure lowering efficacy of renin inhibitors for primary hypertension",firstPublishedDate:"Apr 5, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hypertension Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007066.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007066.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007066.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007066.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007066.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007066.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007066.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007066.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007066.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007066.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5027 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007066.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-sec-0109"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-sec-0045"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-sec-0068"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/appendices#CD007066-sec-0114"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/table_n/CD007066StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/table_n/CD007066StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Blood pressure lowering efficacy of renin inhibitors for primary hypertension</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/information#CD007066-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Vijaya M Musini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/information#CD007066-cr-0003">Kendra AK Lawrence</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/information#CD007066-cr-0004">Patricia M Fortin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/information#CD007066-cr-0005">Ken Bassett</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007066.pub3/information#CD007066-cr-0006">James M Wright</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/information/en#CD007066-sec-0125">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 April 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007066.pub3">https://doi.org/10.1002/14651858.CD007066.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007066-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007066-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007066-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007066-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007066-abs-0004">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007066-abs-0003">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007066-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007066-abs-0001" lang="en"> <section id="CD007066-sec-0001"> <h3 class="title" id="CD007066-sec-0001">Background</h3> <p>Hypertension is a chronic condition associated with an increased risk of mortality and morbidity. Renin is the enzyme responsible for converting angiotensinogen to angiotensin I, which is then converted to angiotensin II. Renin inhibitors are a new class of drugs that decrease blood pressure (BP) by preventing the formation of both angiotensin I and angiotensin II. </p> </section> <section id="CD007066-sec-0002"> <h3 class="title" id="CD007066-sec-0002">Objectives</h3> <p>To quantify the dose‐related BP lowering efficacy of renin inhibitors compared to placebo in the treatment of primary hypertension. </p> <p>To determine the change in BP variability, pulse pressure, and heart rate and to evaluate adverse events (mortality, non‐fatal serious adverse events, total adverse events, withdrawal due to adverse effects and specific adverse events such as dry cough, diarrhoea and angioedema). </p> </section> <section id="CD007066-sec-0003"> <h3 class="title" id="CD007066-sec-0003">Search methods</h3> <p>The Cochrane Hypertension Information Specialist searched the following databases for randomized controlled trials (RCTs) up to February 2017: the Cochrane Hypertension Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (2017, Issue 2), MEDLINE (from 1946), Embase (from 1974), the World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov. There was no restriction by language or publication status. We also searched the European Medicines Agency (EMA) for clinical study reports, the Novartis Clinical Study Results Database, bibliographic citations from retrieved references, and contacted authors of relevant papers regarding further published and unpublished work. </p> </section> <section id="CD007066-sec-0004"> <h3 class="title" id="CD007066-sec-0004">Selection criteria</h3> <p>We included randomized, double‐blinded, placebo‐controlled studies evaluating BP lowering efficacy of fixed‐dose monotherapy with renin inhibitor compared with placebo for a minimum duration of three to 12 weeks in adult patients with primary hypertension. </p> </section> <section id="CD007066-sec-0005"> <h3 class="title" id="CD007066-sec-0005">Data collection and analysis</h3> <p>This systematic review is a comprehensive update which includes four additional studies and extensive detail from nine clinical study reports (CSRs) of previously included studies obtained from EMA. The remaining three CSRs are not available. </p> <p>Two review authors independently assessed study eligibility and extracted data. In all cases where there was a difference between the CSR and the published report, data from the CSR was used. Dichotomous outcomes were reported as risk ratio (RR) with 95% confidence intervals (CIs) and continuous outcomes as mean difference (MD) with 95% CIs. </p> </section> <section id="CD007066-sec-0006"> <h3 class="title" id="CD007066-sec-0006">Main results</h3> <p>12 studies (mean duration of eight weeks) in 7439 mostly Caucasian patients (mean age 54 years) with mild‐to‐moderate uncomplicated hypertension were eligible for inclusion in the review. Aliskiren was the only renin inhibitor evaluated. All included studies were assessed to have high likelihood of attrition, reporting and funding bias. </p> <p>Aliskiren has a dose‐related systolic/diastolic blood pressure (SBP/DBP) lowering effect as compared with placebo MD with 95% CI: aliskiren 75 mg (MD ‐2.97, 95% CI ‐4.76 to ‐1.18)/(MD ‐2.05, 95% CI ‐3.13 to ‐0.96) mm Hg (<i>moderate‐quality evidence</i> ), aliskiren 150 mg (MD ‐5.95, 95% CI ‐6.85 to ‐5.06)/ (MD ‐3.16, 95% CI ‐3.74 to ‐2.58) mm Hg (<i>moderate‐quality evidence</i> ), aliskiren 300 mg (MD ‐7.88, 95% CI ‐8.94 to ‐6.82)/ (MD ‐4.49, 95% CI ‐5.17 to ‐3.82) mm Hg (<i>moderate‐quality evidence),</i> aliskiren 600 mg (MD ‐11.35, 95% CI ‐14.43 to ‐8.27)/ (MD ‐5.86, 95% CI ‐7.73 to ‐3.99) mm Hg (<i>low‐quality evidence</i>). There was a dose‐dependent decrease in blood pressure for aliskiren 75 mg, 150 mg and 300 mg. The blood pressure lowering effect of aliskiren 600 mg was not different from 300 mg (MD ‐0.61, 95% CI ‐2.78 to 1.56)/(MD ‐0.68, 95% CI ‐2.03 to 0.67). Aliskiren had no effect on blood pressure variability<b>.</b> Due to very limited information available regarding change in heart rate and pulse pressure, it was not possible to meta‐analyze these outcomes. </p> <p>Mortality and non‐fatal serious adverse events were not increased. This review found that in studies of eight week duration aliskiren may not increase withdrawal due to adverse events (<i>low‐quality evidence</i> ). Diarrhoea was increased in a dose‐dependent manner (RR 7.00, 95% CI 2.48 to 19.72) with aliskiren 600 mg (<i>low‐quality</i> evidence). The most frequent adverse events reported were headache, nasopharyngitis, diarrhoea, dizziness and fatigue. </p> </section> <section id="CD007066-sec-0007"> <h3 class="title" id="CD007066-sec-0007">Authors' conclusions</h3> <p>Compared to placebo, aliskiren lowered BP and this effect is dose‐dependent. This magnitude of BP lowering effect is similar to that for angiotensin‐converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). There is no difference in mortality, nonfatal serious adverse events or withdrawal due to adverse effects with short term aliskiren monotherapy. Diarrhoea was considerably increased with aliskiren 600 mg. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007066-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007066-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007066-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007066-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007066-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007066-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007066-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD007066-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007066-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007066-abs-0008">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007066-abs-0006" lang="en"> <h3>Blood pressure lowering efficacy of aliskiren</h3> <p><b>Review Question(s)</b>: </p> <p>We wanted to determine if aliskiren was better than placebo for reducing blood pressure in adult patients with raised blood pressure, and whether this drug had increased adverse effects. We also wanted to determine if there was a change in blood pressure variability, pulse pressure, heart rate and withdrawal due to side effects. </p> <p>We searched the available medical literature to find all the trials that had assessed these questions. The data included in this review is up to date as of February 2017. </p> <p><b>Background</b> </p> <p>High blood pressure or hypertension can lead to heart attacks and stroke. A new class of drugs called renin inhibitors is indicated for the treatment of hypertension. Aliskiren is the only drug of the renin inhibitor class that has been studied and approved for treatment of hypertension at this time. </p> <p><b>Study characteristics</b> </p> <p>We found 12 studies, eight weeks in duration, that randomly assigned 7439 adult people with uncomplicated mild‐to‐moderate hypertension to aliskiren at doses ranging from 75 mg to 600 mg or placebo. All studies were funded by the manufacturer Novartis. Detailed information regarding adverse events, obtained from nine clinical study reports submitted to regulators, are included in this update. </p> <p><b>Key Results</b> </p> <p>We concluded that aliskiren is better than placebo at lowering blood pressure and that the magnitude of this effect could be similar to other classes of drugs when 300 mg, which is the maximum recommended dose, is used. Aliskiren 300 mg reduced blood pressure by eight points in the upper number (called systolic blood pressure) and five points in the lower number (called diastolic blood pressure). Aliskiren had no effect on blood pressure changeability. Due to very limited information regarding change in heart rate and pulse pressure (difference between upper and lower number) it was not possible to analyze these outcomes. </p> <p>The studies were too short in duration to assess side effects. Aliskiren did not increase death, non‐fatal serious adverse events or withdrawal due to side effects. The most common adverse events observed were headache, diarrhoea, dizziness and fatigue. Diarrhoea was considerably increased with aliskiren 600 mg as compared to placebo. </p> <p><b>Quality of evidence</b>: The decrease in blood pressure at the recommended dose was rated as moderate‐quality evidence and adverse event data was graded as low‐quality evidence as included studies were assessed to have high likelihood of reporting and funding bias. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007066-sec-0109" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007066-sec-0109"></div> <h3 class="title" id="CD007066-sec-0110">Implications for practice</h3> <section id="CD007066-sec-0110"> <p>The renin inhibitor aliskiren 150 mg and 300 mg lowered systolic and diastolic blood pressure (BP) as compared to placebo in a dose‐dependent manner (moderate‐quality evidence). The findings of this systematic review also suggest that aliskiren 300 mg lowered BP by a magnitude that is similar to what has been determined with angiotensin‐converting‐enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). This review found that in studies of eight‐week duration, aliskiren may not increase withdrawal due to adverse events as compared to placebo (low‐quality evidence). Diarrhoea was increased in a dose‐dependent manner and a substantial increase was observed with aliskiren 600 mg as compared to placebo (low‐quality evidence). All studies meeting the inclusion criteria of this review excluded high‐risk patients therefore generalizing these results for decision making in clinical practice is limited to only adult patients with uncomplicated primary hypertension. </p> </section> <h3 class="title" id="CD007066-sec-0111">Implications for research</h3> <section id="CD007066-sec-0111"> <p>The goal of antihypertensive therapy is to reduce mortality and morbidity. No randomized controlled trial (RCT) has been identified that studies the long‐term effects of renin inhibitors monotherapy on mortality and morbidity versus placebo. More RCTs of longer duration are needed to assess the BP lowering efficacy of renin inhibitors as compared to other classes of antihypertensive drugs. All published RCTs must provide data on all outcomes and all negative studies need to be published, in order for this review to provide an accurate summary of the best available evidence. </p> <p>The Food and Drug Administration (FDA) has recently issued a warning about combining aliskiren with ACEIs and ARBs in patients diagnosed with diabetes or renal impairment. Therefore long‐term mortality and morbidity data in patients with primary hypertension on monotherapy with renin inhibitors should be a priority. There is an urgent need to go beyond surrogate biomarker and obtain harm‐benefit data from clinical endpoint studies to better inform clinical decisions. There is growing evidence that the surrogate marker ‐ the lowering of BP ‐ is inadequate in predicting health outcomes with antihypertensive therapy (<a href="./references#CD007066-bbs2-0098" title="WrightJM , MusiniVM . First‐line drugs for hypertension. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD001841.pub2] ">Wright 2009</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007066-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007066-sec-0036"></div> <div class="table" id="CD007066-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Aliskiren compared to placebo for primary hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: primary hypertension </p> <p><b>Setting</b>: Outpatient </p> <p><b>Intervention</b>: Aliskiren </p> <p><b>Comparison</b>: Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b> Anticipated absolute effects<sup>*</sup> (95% CI)mmHg</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Effect with placebo<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Effect with Aliskiren<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP ‐ Aliskiren 75 mg vs. placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.9 lower to 10.0 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.97 lower (4.76 lower to 1.18 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1100<br/> (5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP ‐ Aliskiren 150 mg vs. placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.0 lower to 10.0 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5.95 lower (6.85 lower to 5.06 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3786<br/> (12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE 4 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP ‐ Aliskiren 300 mg vs. placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.9 lower to 10.0 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7.88 lower (8.94 lower to 6.82 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3009<br/> (10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE 5 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP ‐ Aliskiren 600 mg vs. placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3.8 lower to 5.3 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11.35 lower (14.43 lower to 8.27 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>393<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊝⊝</b> <br/> LOW <sup>6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diastolic BP ‐ Aliskiren 75 mg vs placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3.2 lower to 8.6 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.05 lower (3.13 lower to 0.96 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1100<br/> (5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diastolic BP ‐ Aliskiren 150 mg vs placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3.0 lower to 8.6 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3.16 lower (3.74 lower to 2.58 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3783<br/> (12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diastolic BP ‐ Aliskiren 300 mg vs placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3.2 lower to 8.6 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4.49 lower (5.17 lower to 3.82 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3001<br/> (10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diastolic BP ‐ Aliskiren 600 mg vs placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6.2 lower to 6.3 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5.86 lower (7.73 lower to 3.99 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>393<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊝⊝</b> <br/> LOW <sup>6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diarrhoea ‐</b> </p> <p>Aliskiren 600 mg vs placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>14 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>95 per 1,000</b> <br/> (34 to 266) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 7.00<br/> (2.48 to 19.72)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>592<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊝⊝</b> <br/> LOW <sup>6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>MD:</b> Mean Difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Range of mean decrease in SBP and DBP mmHg as compared to baseline in the individual trials in the placebo group. </p> <p>2. Effects in Aliskiren group represent the blood pressure lowering effect in excess of that with placebo. </p> <p>3. Downgraded by 1 level for serious risk of bias (due to high likelihood of attrition, selective reporting and funding bias in all 5 included studies). Also study <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> had high likelihood of selection bias. </p> <p>4. Downgraded by one level for serious risk of bias (due to high likelihood of attrition, selective reporting and funding bias in all 12 included studies). </p> <p>5. Downgraded by one level for serious risk of bias (due to high likelihood of attrition, selective reporting and funding bias in all 10 included studies). </p> <p>6. Downgraded by 1 level for serious risk of bias (due to high likelihood of attrition, selective reporting and funding bias in both included studies). </p> <p>7. Downgraded by 1 more level due to wide confidence interval.</p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007066-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007066-sec-0037"></div> <section id="CD007066-sec-0038"> <h3 class="title" id="CD007066-sec-0038">Description of the condition</h3> <p>Hypertension is defined as a systolic blood pressure (SBP) of 140 mmHg or greater and/or diastolic blood pressure (DBP) of 90 mmHg or greater in people who are not taking antihypertensive medication. (<a href="./references#CD007066-bbs2-0085" title="PoulterNR , PrabhakaranD , CaulfieldM . Hypertension. Lancet 22nd August 2015;386(9995):801‐12. ">Poulter 2015</a>). It is a chronic condition associated with an increased risk of mortality and morbidity from stroke, coronary heart disease, congestive heart failure, and renal disease. For patients with established hypertension, blood pressure should first be managed with life‐style and behaviour modification. However, if these measures prove inadequate then pharmacotherapy is indicated. </p> </section> <section id="CD007066-sec-0039"> <h3 class="title" id="CD007066-sec-0039">Description of the intervention</h3> <p>The renin‐angiotensin‐aldosterone system (RAAS) is a hormone system that regulates blood pressure and fluid balance. When renal blood flow is reduced, the kidney converts prorenin to renin and secretes it directly into the circulation. Plasma renin then converts angiotensinogen released by the liver to angiotensin I. Angiotensin I is subsequently converted to angiotensin II by the angiotensin‐converting enzyme (ACE) found in the lungs. This causes blood vessels to constrict, resulting in increased blood pressure. Angiotensin II also stimulates the secretion of the hormone aldosterone from the adrenal cortex, which causes the tubules of the kidney to increase the reabsorption of sodium and water into the blood. This increases the volume of the extracellular fluid in the body, which also increases blood pressure. </p> <p>RAAS is an important target site for five distinctive antihypertensive drug classes: beta blockers, renin inhibitors, angiotensin‐converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs) and aldosterone inhibitors. </p> </section> <section id="CD007066-sec-0040"> <h3 class="title" id="CD007066-sec-0040">How the intervention might work</h3> <p>The RAAS is a major regulator of cardiovascular homeostasis, in which the vasoactive peptide, angiotensin II, plays a central role. ACEIs and ARBs block this system by inhibiting the generation and action of angiotensin II, respectively. Although ACEIs and ARBs have proven effective, these agents do not block the RAAS completely. Whereas ACEIs and ARBs block the RAAS further downstream, renin inhibitors prevent the formation of renin, the enzyme that catalyses the conversion of angiotensinogen to angiotensin I, the rate‐limiting step in this cascade. Renin is responsible for all "downstream" events leading to production of angiotensin II and subsequent stimulation of its receptors. </p> <p>Attempts to block renin began in the 1950s with the use of renin antibodies (<a href="./references#CD007066-bbs2-0064" title="HelmerOM . Studies on renin antibodies. Circulation1958;17(4 part 2):648‐52. ">Helmer 1958)</a>. Issues of potency, bioavailability, duration of action and cost of synthesis have marred the drug development of renin inhibitors. For example, potent renin inhibitors such as remikiren and enalkiren had low oral bioavailability (<a href="./references#CD007066-bbs2-0058" title="FrishmanWH , FozailoffA , LinC , DikeC . Renin inhibition: a new approach to cardiovascular therapy. Journal of Clinical Pharmacology1994;34:873‐80. ">Frishman 1994)</a>. Newer drugs such as zankiren and terlakiren looked more promising, but further development was halted in the mid 1990s with the development of ARBs. </p> <p>More recent programmes to develop renin inhibitors have been based on X‐ray crystallography of renin's active site with computational modelling rather than based on the structure of angiotensinogen (<a href="./references#CD007066-bbs2-0073" title="KrumH , GilbertRE . Novel therapies blocking the renin‐angiotensin‐aldosterone system in the management of hypertension and related disorders. Journal of Hypertension2007;25:25‐35. ">Krum 2007)</a>. This has led to aliskiren, a new non‐peptide, low molecular weight, orally active renin inhibitor, which has been approved in the USA, Canada and other countries for the treatment of hypertension. </p> </section> <section id="CD007066-sec-0041"> <h3 class="title" id="CD007066-sec-0041">Why it is important to do this review</h3> <p>ACEIs and ARBs block the RAAS downstream whereas renin inhibitors prevent the formation of renin, which is responsible for all "downstream" events leading to production of angiotensin II and subsequent stimulation of its receptors. It has been speculated that renin inhibitors might provide a more effective means of blockade of the RAAS than is possible with ACEIs or ARBs (<a href="./references#CD007066-bbs2-0054" title="DuprezD . Role of the renin–angiotensin–aldosterone system in vascular remodeling and inflammation: a clinical review. Journal of Hypertension2006;24:983‐91. ">Duprez 2006)</a>. </p> <p>Two Cochrane reviews (<a href="./references#CD007066-bbs2-0065" title="HeranBS , WongMMY , HeranIK , WrightJM . Dose‐related blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors in the treatment of primary hypertension. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD003823] ">Heran 2008a</a>; <a href="./references#CD007066-bbs2-0066" title="HeranBS , WongMMY , HeranIK , WrightJM . Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD003822.pub2] ">Heran 2008b</a>) have quantified the dose ranging blood pressure lowering efficacy of both ACEIs and ARBs as compared to placebo using similar methodology. This review was done to determine the dose ranging blood pressure lowering efficacy and adverse effects of renin inhibitors as compared to placebo and to compare the magnitude of reduction in blood pressure with ACEIs and ARBs. </p> <p>It is important to note that a new methodological approach was undertaken to update this review by actively seeking out information available from all possible sources instead of relying on the very limited information available in the journal‐published trials included in the previous update of this review. For this update, a formal request for all relevant clinical study reports (CSRs) was made to the European Medicines Agency (EMA) under the Access to Documents Policy (0043). Information regarding an individual study was obtained from additional web sites: ClinicalTrials.gov, EU Clinical Trial Register, and Novartis Clinical Trial Results Database. </p> <p>Cochrane reviews typically rely on journal‐published trials for critical appraisal of study conduct, methods and, if appropriate, for meta‐analysis of study data. However, reliance on journal‐published studies may pose a threat to the validity of a meta‐analysis due to levels of bias introduced by the published versions of these trials (<a href="./references#CD007066-bbs2-0055" title="DwanK , GambleC , WilliamsonPR , KirkhamJJ , for the Reporting Bias Group. Systematic review of the empirical evidence of study publication bias and outcome reporting bias ‐ an updated review. PloS One2013;8(7):1‐38. ">Dwan 2013</a>). Reporting bias is particularly relevant with respect to our decision to use data from regulatory sources, rather than solely rely on journal‐published studies, for this systematic review. At the study level reporting bias may occur when studies are not submitted or are rejected for publication (<a href="./references#CD007066-bbs2-0050" title="ChalmersI . Underreporting research is scientific misconduct. JAMA1990;263(10):1405‐8. ">Chalmers 1990</a>); at the outcome level reporting bias can occur as a result of selective non‐reporting of outcomes. The latter in particular has been described as an under‐recognized level of bias that serves to undermine the validity of systematic reviews (<a href="./references#CD007066-bbs2-0068" title="HodkinsonA , KirkhamJ , Tudur‐SmithC , GambleC . Reporting of harms data in RCTs: a systematic review of empirical assessments against the CONSORT harms extension. BMJ2013;3:1‐9. ">Hodkinson 2013</a>; <a href="./references#CD007066-bbs2-0072" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:637‐40. ">Kirkham 2010</a>; <a href="./references#CD007066-bbs2-0079" title="McGauranN , WieselerB , KreisJ , SchulerYB , KolschH , KaiserT . Reporting bias in medical research ‐ a narrative review. Trials2010;11:1‐15. ">McGauran 2010</a>). Despite being considered one of the highest forms of evidence, systematic reviews may merely further the misrepresentation of journal‐published study data. </p> <p>In an effort to correct for reporting bias, there has been an increased effort to access clinical study reports (<a href="./references#CD007066-bbs2-0059" title="GotzscheP , JorgensonAW . Opening up data at the European Medicines Agency. BMJ2011;343:1184‐6. ">Gotzsche 2011</a>), which have been described as "the most complete synthesis of the planning, execution, and results of a clinical study" (<a href="./references#CD007066-bbs2-0052" title="DoshiP , JeffersonT , DelMarC . The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Medicine2012;9(4):1‐6. ">Doshi 2012</a>). These documents are required by regulatory authorities for market approval purposes and may also be produced for ongoing safety evaluations. Compared to journal‐published trials, CSRs do not require compression for journal publication, but are composed of thousands of pages that include multiple data sets on all pre‐specified outcome measures, numerous tables, figures and patient narratives (<a href="./references#CD007066-bbs2-0071" title="JeffersonT . Facing the unreliability of clinical trials literature. Drug and Therapeutics Bulletin of Navarre, Spain2015;22(2):1‐11. ">Jefferson 2015</a>). A growing number of systematic reviews that rely on CSRs suggest that the data reported in journal‐published trials, as a result of discrepant reporting or non‐reporting, do indeed often lead to a misinformed representation of the evidence (<a href="./references#CD007066-bbs2-0056" title="EydingD , LelgemannM , GrouvenU , HarterM , KrompM , KaiserT , et al. Reboxetine for acute treatment of major depression: systematic review and meta‐analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ2010;341:816. ">Eyding 2010</a>; <a href="./references#CD007066-bbs2-0070" title="JeffersonT , JonesMA , DoshiP , DelMarCB , HamaR , ThompsonMJ , et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD008965.pub4] ">Jefferson 2014</a>; <a href="./references#CD007066-bbs2-0091" title="SharmaT , GuskiLS , FreundN , GøtzscheP . Suicidality and aggression during antidepressant treatment: systematic review and meta‐analyses based on clinical study reports. BMJ2016;352(65):1‐10. ">Sharma 2016</a>). Additionally, studies that directly compare the reporting of harms between CSRs and journal‐published trials reveal the extent of reporting bias, and the distorted representation of safety within journal publications (<a href="./references#CD007066-bbs2-0069" title="HodkinsonA , GambleC , SmithCT . Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials. Trials2016;17(1):1‐11. ">Hodkinson 2016</a>; <a href="./references#CD007066-bbs2-0078" title="MaundE , TendalB , HrobjartssonA , JorgensonK , LundhA , SchrollJ , et al. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ2014;348:1‐9. ">Maund 2014</a>; <a href="./references#CD007066-bbs2-0097" title="WieselerB , ChrysantSG , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , et al. Impact of document type on reporting ality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ2012;344:1‐11. ">Wieseler 2012</a>). Lacking access to the full complement of evidence, systematic reviews may serve to influence health policy and prescribing practices that result in harm or lack of benefit, a burden directly borne by the patient. </p> <p>In light of these considerations, we took a relatively new methodological approach to rely more heavily on regulatory sources of data. We chose to include data from the US Food and Drug Administration medical review (<a href="./references#CD007066-bbs2-0057" title="Center for drug evaluation and research. Tekturna (Aliskiren) Medical Review. FDA database March 5th 2007, issue Application number 21‐985:1‐283. ">FDA Medical Review 2007</a>) within the 2017 update of this systematic review (<a href="./references#CD007066-bbs2-0063" title="Hart2012 . Effect of reporting bias on meta‐analyses of drug trials reanalysis of meta‐analyses. BMJ2012;344:13. ">Hart 2012</a>; <a href="./references#CD007066-bbs2-0088" title="RisingK , BacchettP , BeroL . Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Medicine2008;5(11):1561‐70. ">Rising 2008</a>), and CSRs obtained through the European Medicine Agency's Access to Documents policy (0043). Though the process of obtaining CSRs and navigating the large volume of these documents is time‐consuming (<a href="./references#CD007066-bbs2-0053" title="DoshiP , JeffersonT . Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. Trials2016;17(78):1‐7. ">Doshi 2016</a>), the motivation to do so stems from a desire to create a review that is based upon transparent and complete data, and is essentially of greater value for our readers. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007066-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007066-sec-0042"></div> <section id="CD007066-sec-0043"> <h3 class="title" id="CD007066-sec-0043">Primary objective</h3> <p>To determine the dose ranging blood pressure lowering efficacy of fixed dose renin inhibitor monotherapy as compared with placebo over a period of three to 12 weeks in adult patients with primary hypertension. </p> </section> <section id="CD007066-sec-0044"> <h3 class="title" id="CD007066-sec-0044">Secondary objectives</h3> <p>To determine whether renin inhibitors affect blood pressure variability, pulse pressure, and heart rate as compared with placebo. </p> <p>To document adverse events of renin inhibitors as compared with placebo (including mortality, non‐fatal serious adverse events, total adverse events, withdrawal due to adverse effects and specific adverse events such as dry cough, diarrhoea and angioedema). </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007066-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007066-sec-0045"></div> <section id="CD007066-sec-0046"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007066-sec-0047"> <h4 class="title">Types of studies</h4> <p>We included published and unpublished study reports of double‐blind, randomized, placebo‐controlled trials that randomly allocated patients to a fixed dose of renin inhibitor monotherapy or parallel placebo with duration of follow‐up of at least three weeks in adult patients with primary hypertension. There were no limits on language or publication status. Studies reported blood pressure measurements at baseline (following washout) and at one or more time points between three and 12 weeks post‐treatment on a fixed dose of drug. </p> </section> <section id="CD007066-sec-0048"> <h4 class="title">Types of participants</h4> <p>Using a standard method of measurement, such as a calibrated standard mercury sphygmomanometer, adult participants had to have a baseline blood pressure of at least 140 mm Hg systolic and/or a diastolic blood pressure of at least 90 mm Hg. Participants could not have a creatinine levels greater than 1.5 times the normal level. Participants were not restricted by age, gender, baseline risk or any other co‐morbid conditions. </p> </section> <section id="CD007066-sec-0049"> <h4 class="title">Types of interventions</h4> <p>Intervention included monotherapy with different fixed doses of renin inhibitor. Control group received a placebo. Data from study or arms of study in which titration to a higher dose was based on blood pressure response were not eligible. However, if a lower fixed dose was used for minimum of three weeks and then in all patients aliskiren was force titrated to a fixed higher dose for at least three weeks duration, then data at both doses were used from the same study to evaluate dose response. </p> </section> <section id="CD007066-sec-0050"> <h4 class="title">Types of outcome measures</h4> <section id="CD007066-sec-0051"> <h5 class="title">Primary outcomes</h5> <p>1. Change from baseline of trough and/or peak systolic and diastolic blood pressure over a minimum time frame of three weeks. </p> </section> <section id="CD007066-sec-0052"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007066-list-0001"> <li> <p>Change in standard deviation of blood pressure.</p> </li> <li> <p>Change in pulse pressure.</p> </li> <li> <p>Change in heart rate.</p> </li> <li> <p>Adverse events (including mortality, non‐fatal serious adverse events, total adverse events, withdrawal due to adverse effects and specific adverse events such as dry cough, diarrhoea and angioedema). </p> </li> </ol> </p> <p>All secondary outcomes were assessed over a minimum time frame of three weeks and measured at the end of follow‐up period. </p> </section> </section> </section> <section id="CD007066-sec-0053"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007066-sec-0054"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Hypertension Information Specialist conducted systematic searches in the following databases for randomized controlled trials without language, publication year or publication status restrictions: </p> <p> <ol id="CD007066-list-0002"> <li> <p>the Cochrane Hypertension Specialised Register via the Cochrane Register of Studies (CRS‐Web) (searched 12 February 2017); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 2) via the Cochrane Register of Studies (CRS‐Web) (searched 12 February 2017); </p> </li> <li> <p>MEDLINE Ovid (from 1946 onwards), MEDLINE Ovid Epub Ahead of Print, and MEDLINE Ovid In‐Process &amp; Other Non‐Indexed Citations (searched 12 February 2017); </p> </li> <li> <p>Embase Ovid (searched 12 February 2017);</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) searched 12 February 2017); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>) searched 12 February 2017). </p> </li> </ol> </p> <p>The Information Specialist modelled subject strategies for databases on the search strategy designed for MEDLINE. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomized controlled (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1.0, Box 6.4.b. (<a href="./references#CD007066-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.10 [updated March 2011]. Available from www.cochrane‐handbook.org: The Cochrane Collaboration, 2011. ">Higgins 2011</a>)). Search strategies for major databases are provided in <a href="./appendices#CD007066-sec-0115">Appendix 1</a>. </p> </section> <section id="CD007066-sec-0055"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD007066-list-0003"> <li> <p>The Cochrane Hypertension Information Specialist searched the Hypertension Specialised Register segment (which includes searches of MEDLINE and Epistemonikos for systematic reviews) to retrieve existing systematic reviews relevant to this systematic review, so that we could scan their reference lists for additional trials. </p> </li> <li> <p>We checked the bibliographies of included studies and any relevant systematic reviews identified for further references to relevant trials. </p> </li> <li> <p>Where necessary, we contacted authors of key papers and abstracts to request additional information about their trials. </p> </li> <li> <p>We did not perform a separate search for adverse effects of interventions used for the treatment of hypertension. We considered adverse effects described in included studies only. </p> </li> </ol> </p> <p>In preparation for the 2017 update, a formal request for all relevant clinical study reports (CSRs) was made to the European Medicines Agency (EMA) under the Access to Documents Policy (0043). Additionally, an enquiry for all relevant CSRs was submitted to Clinical Study Data Request (CSDR) (<a href="https://clinicalstudydatarequest.com" target="_blank">https://clinicalstudydatarequest.com</a>), the data sharing platform to which the manufacturer, Novartis, belongs. We also searched the Novartis Clinical Trial Results Database (<a href="https://www.novctrd.com" target="_blank">https://www.novctrd.com</a>). </p> <p>Review author KL submitted an enquiry to Novartis on the data sharing platform to which this company belongs, www.clinicalstudydatarequest.com (CSDR) on 17 October 2015 with respect to 12 studies that met the inclusion criteria for this review. Placing an enquiry is a step recommended if studies are not listed on the platform for data‐sharing. The Novartis data holder is expected to respond to the enquiry regarding potential for data‐sharing privileges to be granted. Two separate attempts were made to request a response from the data holder using the CSDR platform on 11 November 2015 and 20 January 2016. Unfortunately, we have not received a response from Novartis to date. CSDR Support has also made repeated attempts to elicit a response from the Novartis data holder to our enquiry without success. </p> </section> </section> <section id="CD007066-sec-0056"> <h3 class="title" id="CD007066-sec-0056">Data collection and analysis</h3> <section id="CD007066-sec-0057"> <h4 class="title">Selection of studies</h4> <p>Two review authors (VM and PF) independently screened the titles and the abstracts resulting from the search strategies from 2008 until October 2014. Two review authors (VM and KL) independently screened the titles and the abstracts resulting from the search strategies from October 2014 until February 2017. Articles were rejected on initial screening if it was judged from the title or the abstract that the article was not a report of a randomized placebo‐controlled study. We retrieved the full text of the remaining articles. The bibliographies of pertinent articles, reviews and texts were searched for additional citations. </p> <p>Two review authors independently (VM and KL or PF) assessed the eligibility of the studies using a study selection form. We resolved discrepancies by discussion, and when necessary by a third author (JMW or KB). </p> </section> <section id="CD007066-sec-0058"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (VM and PF or KL) extracted data independently and cross‐checked them. All numeric calculations and graphic interpolations were confirmed by a second person. </p> <p>This update relied on data from nine CSRs (not including appendices) received to date instead of their respective journal‐published study: 1) <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>, 2) <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>, 3) <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>, 4) <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>, 5) <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a> 6) <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>, 7) <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>, 8) <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> and 9) <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>. The 9th CSR is of the study <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>, which to date has no corresponding journal‐published trial. </p> <p>The EMA does not possess CSRs of the three remaining studies meeting the inclusion criteria. </p> <p>1. <a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>: Provided this trial does not have a corresponding journal‐published trial, we have relied on the results available on the ClinicalTrials.gov web site for this study. </p> <p>2. <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>: We have relied on the journal‐published report; additionally, results have been posted on the Novartis Clinical Trial Results Database, as well as results posted on ClinicalTrials.gov web site. </p> <p>3. <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>: We have relied on the journal‐published report; additionally, results have been posted on Novartis Clinical Trial Results database. This study was not registered on ClinicalTrials.gov web site. </p> <p>In all cases where there was a difference between the CSR and published report, data from the CSR was used. </p> </section> <section id="CD007066-sec-0059"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently (VM and PF or KL) assessed the risk of bias of all included studies and prepared a 'Risk of bias' table. </p> <p>Since our access to information for each included study differed based on the availability of CSRs, and/or results posted on Novartis Clinical Trial Results Database and/or results posted on ClinicalTrials.gov web site, our approach to evaluating the risk of bias of each study is based on differing availability of information. </p> <p>1. Within CSRs, we found that the details on methods are generally reported more extensively than in journal‐published article. Since appendices were not included with the CSRs received by the EMA (their arrival is pending), we chose to assess a level of bias as 'unclear risk' when details on methods were insufficiently reported or not reported at all within a CSR. In the future update of this review, we will include information from the CSR appendices which are being requested from the EMA. Provided that <a href="./references#CD007066-bbs2-0070" title="JeffersonT , JonesMA , DoshiP , DelMarCB , HamaR , ThompsonMJ , et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD008965.pub4] ">Jefferson 2014</a> had access to CSRs with appendices for review, we could not follow their approach to assess a level of bias as 'high risk' of bias instead of 'unclear risk' when details on methods are insufficiently reported or not reported at all within a CSR. </p> <p>2. For situations where we did not have access to the corresponding CSR of a journal‐published trial, the 'Risk of bias' assessment was conducted according to the journal‐published trial in accordance with the criteria established in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007066-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.10 [updated March 2011]. Available from www.cochrane‐handbook.org: The Cochrane Collaboration, 2011. ">Higgins 2011</a>). </p> <p>3. As a result of not having access to either the CSR or journal‐published study, we relied on clinical study synopses available on ClinicalTrials.gov for one study that met our inclusion criteria (<a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>). As these synopses are even more compressed in terms of reporting than journal‐published studies, we did not assume 'high risk' of bias for random sequence generation, allocation concealment or blinding if the methods were not described; rather, we rated them as 'unclear', or if described sufficiently, as 'low risk' of bias. </p> </section> <section id="CD007066-sec-0060"> <h4 class="title">Measures of treatment effect</h4> <p>Mean difference was used in the meta‐analyses in this version and the previous version to report continuous outcomes such as change in SBP and DBP and the effect size is reported as MD with 95% confidence intervals (CIs). </p> <p>Relative risk was used in the meta‐analyses in this version and the previous version to report dichotomous outcomes such as mortality, non‐fatal serious adverse events, withdrawal due to adverse effects and specific adverse events and the effect size is reported as RR with 95% CIs. </p> </section> <section id="CD007066-sec-0061"> <h4 class="title">Unit of analysis issues</h4> <p>In the 12 included studies, although sitting trough SBP and DBP measurements were reported at different time points within each study, we have included data at the longest period of follow‐up on the monotherapy dose. Ten of the 12 included studies were of eight weeks duration and data at this time point was included in the analyses. From one study <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>, 26 weeks in duration, data reported at three weeks on aliskiren monotherapy were used. Study <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> was 13 weeks in duration, but data reported at the end of the double‐blind period at eight weeks were included in the analyses. </p> </section> <section id="CD007066-sec-0062"> <h4 class="title">Dealing with missing data</h4> <p>In the original review (<a href="./references#CD007066-bbs2-0102" title="MusiniVM , FortinPM , BassettK , WrightJM . Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD007066.pub2] ">Musini 2008b</a>) and the first update in 2011, in the case of missing values for standard deviation of the change in blood pressure, the standard deviation was imputed based on the information in the same study or from other studies using the same dose. The following hierarchy (listed from high to low preference) was used to impute standard deviation values. </p> <p> <ol id="CD007066-list-0004"> <li> <p>Standard deviation of change in blood pressure data from a different position (standing or supine). </p> </li> <li> <p>Standard deviation of blood pressure at the end of treatment.</p> </li> <li> <p>Standard deviation of blood pressure at baseline (except if this measure is used for entry criteria) (<a href="./references#CD007066-bbs2-0080" title="MusiniVM , WrightJM . Factors affecting blood pressure variability: lessons learned from two systematic reviews of randomized controlled trials. PLoS One2009;4(5):e5673. [DOI: 10.1371/journal.pone.0005673] ">Musini 2009</a>). </p> </li> <li> <p>Mean standard deviation of change in blood pressure from other studies using the same class of drug. </p> </li> </ol> </p> <p>In this 2017 update, we were able to include full reporting of mean sitting SBP (MSSBP) and mean sitting DBP (MSDBP) data with standard deviation (SD), least square means (LSMs) of change in MSSBP and MSDBP with standard error of the mean (SEM) from eight CSRs of published studies (<a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>; <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>; <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>; <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>), and from one CSR of an unpublished study <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>. Therefore, the reduction in LSM of change in SBP and DBP data including SD or SEM reported in this update may vary from previous versions of the review. </p> <p>In study <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> patients were on aliskiren 150 mg dose until week 3 after which patients were force titrated to 300 mg until week 6. After week 6, patients initially randomized to placebo were re‐randomized to receive aliskiren 300 mg or hydrochlorothiazide (HCTZ) 25 mg in a 1:1 ratio. As there is no parallel placebo group after week 6, only data for change in MSDBP and MSSBP at week 3 for aliskiren 150 mg dose and at week 6 for aliskiren 300 mg dose is useful. The data for mean change in MSDBP with SEM was obtained from (CSR Page 84). The CSR did not report this information at week 3. Change in MSDBP and MSSBP at week 3 and for MSSBP at week 6 were estimated from the graphs (figure 3 in the published journal article). The SD's were imputed from the baseline SD for MSSBP (SD at baseline =11.2) and since the SD's were unusually low as reported in the baseline characteristics for MSDBP SD (3.3) the SD's were imputed from the average SD for all studies using aliskiren 150 mg dose or aliskiren 300 mg dose respectively . </p> <p>Since CSRs are not available for two published studies <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a> and <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> the missing values for standard error were imputed as follows: </p> <p>In study <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>, the change in MSDBP and MSSBP from baseline with standard deviation of change for placebo and aliskiren 75 mg, 150 mg and 300 mg at week 8 are reported from Novartis Clinical Trial Results Database. </p> <p>In study <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>, the change in MSDBP and MSSBP from baseline with standard deviation of change for placebo, aliskiren 150 mg and 300 mg at week 8 are reported from the clinical study synopses as reported on ClinicalTrials.gov (NCT00739973). </p> <p>For the unpublished study <a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> for which CSR is not available with EMA, the change in MSDBP and MSSBP from baseline with standard deviation of change for placebo and aliskiren 150 mg at week 8 are reported from clinical synopses posted on ClinicalTrials.gov (NCT01237223). </p> </section> <section id="CD007066-sec-0063"> <h4 class="title">Assessment of heterogeneity</h4> <p>Test for heterogeneity of treatment effect between the studies was done using a standard Chi<sup>2</sup> statistic for heterogeneity. The fixed‐effect model was applied to obtain summary statistics of pooled studies, unless significant between‐study heterogeneity was present, in which case the random‐effects model was used to test statistical significance. </p> </section> <section id="CD007066-sec-0064"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess publication bias using a funnel plot if at least 10 studies met the inclusion criteria. In this version of the review we did not use a funnel plot to assess publication bias. </p> </section> <section id="CD007066-sec-0065"> <h4 class="title">Data synthesis</h4> <p>Data synthesis and analyses were carried out using the Cochrane Review Manager software, RevMan 5.3. </p> <p>The least square means (LSMs) reporting of blood pressure data is non‐robust to data outliers, particularly if outliers have a skewed distribution. This can cause an increase in type 2 errors, however it is not known if there were significant outliers in the data. </p> </section> <section id="CD007066-sec-0066"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The following subgroup analyses were planned a priori.</p> <p> <ol id="CD007066-list-0005"> <li> <p>Race: black, white, other (Asian)</p> </li> <li> <p>Age: adults (18 to 64 years), elderly (65 years or years old)</p> </li> <li> <p>Gender</p> </li> <li> <p>Baseline severity of hypertension: mild, moderate, severe</p> </li> </ol> </p> <p>Since none of the included studies provided data for specific age groups, gender, race or baseline severity of hypertension, we could not perform these analyses. However, the <a href="./references#CD007066-bbs2-0057" title="Center for drug evaluation and research. Tekturna (Aliskiren) Medical Review. FDA database March 5th 2007, issue Application number 21‐985:1‐283. ">FDA Medical Review 2007</a> provided additional information regarding mean placebo‐corrected change from baseline in BP by dose and gender (<i>see</i><a href="#CD007066-tbl-0002">Table 1</a>); dose and age (<i>see</i><a href="#CD007066-tbl-0003">Table 2</a>); and dose and race (<i>see</i><a href="#CD007066-tbl-0004">Table 3</a>) from five placebo‐controlled studies (<a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>). This information is described in <a href="#CD007066-sec-0085">Effects of interventions</a>. </p> <div class="table" id="CD007066-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reported as table 21 in the FDA medical review (page 51): Reviewers mean placebo‐corrected change from baseline in BP by dose and gender based on 5 placebo controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Female</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Male</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>150 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>300 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>600 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD007066-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Reported as table 22 in the FDA medical review (page 51): Reviewers mean placebo‐corrected change from baseline in BP by dose and age based on 5 placebo controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Age &lt; 65 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Age &gt; 65 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>150 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>300 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>600 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.4</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD007066-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reported as table 23 in the FDA medical review (page 52): Reviewers mean placebo‐corrected change from baseline in BP by dose and race based on 5 placebo controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>White</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Black</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Asian</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>150 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>300 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>600 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.4</p> </td> </tr> </tbody> </table> </div> <p>When heterogeneity was significant, we planned to investigate the factors contributing to heterogeneity such as differences in population characteristics or response to placebo that would possibly explain the reason for heterogeneity. However, no significant heterogeneity (I<sup>2</sup> &gt; 50%) was found for any outcome measure. </p> </section> <section id="CD007066-sec-0067"> <h4 class="title">Sensitivity analysis</h4> <p>To test the robustness of the results several sensitivity analyses were planned a priori to be performed. </p> <p> <ol id="CD007066-list-0006"> <li> <p>Studies of high risk of bias versus low risk of bias</p> </li> <li> <p>Studies that were industry‐sponsored versus non‐industry sponsored</p> </li> <li> <p>Studies that assess the drug as primary drug of investigation versus those that assess the drug as comparator </p> </li> <li> <p>Studies with blood pressure data measured in the sitting position versus other measurement positions </p> </li> <li> <p>Studies with published standard deviations of blood pressure change versus imputed standard deviation </p> </li> </ol> </p> <p>Sensitivity analyses could not be done as all studies had similar risks of bias; all studies were industry sponsored; aliskiren was the primary drug of investigation; all studies reported mean sitting trough SBP and DBP; and standard deviation was imputed only in one study (<a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>). </p> <p>We conducted a sensitivity analyses to look for differences in the magnitude of SBP and DBP reduction due to inclusion of information from CSRs in this update compared to previous update in 2011 which included information only from published journal articles. Additional information obtained from CSRs in this update did not result in altering the magnitude of reduction in MSSBP and MSDBP at any dose as compared to placebo from the previous 2011 update as the 95% CIs overlapped. See <a href="#CD007066-tbl-0005">Table 4</a> </p> <div class="table" id="CD007066-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparing MSSBP and MSDBP effect size of previous review versus present update after obtaining information from Clinical study Reports</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Dose of Aliskiren mg/day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Previous version without access to information from CSR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Present version with access to information from CSR</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSSBP mmHg</b> </p> <p><b>MD with 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSDBP mmHg</b> </p> <p><b>MD with 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSSBP mmHg</b> </p> <p><b>MD with 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSDBP mmHg</b> </p> <p><b>MD with 95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aliskiren 75 mg vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.64 (‐4.06 to ‐1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.07 (‐2.94 to ‐1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.97 (‐4.76 to ‐1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.05 (‐3.13 to ‐0.96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aliskiren 150 mg vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.55 (‐6.39 to ‐4.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.91 (‐3.46 to ‐2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.95 (‐6.85 to ‐5.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.16 (‐3.74 to ‐2.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aliskiren 300 mg vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.93 (‐8.77 to ‐7.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.76 (‐5.33 to ‐4.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.88 (‐8.94 to ‐6.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.49 (‐5.17 to ‐3.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aliskiren 600 mg vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.36 (‐13.53 to ‐9.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.57 (‐7.92 to ‐5.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.35 (‐14.43 to ‐8.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.86 (‐7.73 to ‐3.99)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>MSSBP:</b> mean sitting systolic blood pressure; <b>MSDBP:</b> mean sitting diastolic blood pressure; </p> </div> </div> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007066-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007066-sec-0068"></div> <section id="CD007066-sec-0069"> <h3 class="title">Description of studies</h3> <section id="CD007066-sec-0070"> <h4 class="title">Results of the search</h4> <p>From our search strategy we identified 862 study reports: 250 when the original search was run in 2008, another 172 when the review was updated in June 2011 and another 440 for the update in February 2017. Of these, 634 were duplicates or not relevant to this review. </p> <p>We retrieved 46 articles for detailed evaluation: 8 for the initial version of this review in 2008, another 10 for the June 2011 update and another 28 for the current update in February 2017. </p> <p>A total of 12 studies met the inclusion criteria: six published studies for the initial version of this review in 2008 (<a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>, <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>, <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>, <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>, <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>, <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>), another two published studies for the June 2011 update (<a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>, and <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>), and another four for the most recent update in February 2017, two of which are published studies (<a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>, <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>), and two are unpublished studies (<a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> and <a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>). See PRISMA Study flow diagram (<a href="#CD007066-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007066-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA Study flow diagram." data-id="CD007066-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA Study flow diagram.</p> </div> </div> </div> <p>See <a href="#CD007066-tbl-0006">Table 5</a> for detailed information regarding identifier for individual studies meeting the inclusion criteria. All included study have been identified in this update using Novartis Clinical Trial Results Database study identifier number as opposed to the journal‐published author name and year, which were used in the previous two versions of this review. </p> <div class="table" id="CD007066-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study identifier(s) in various websites of individual studies meeting the inclusion criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Novartis Clinical Trial Results Database identifier</b> </p> <p><b>used for study identification</b> </p> <p><b>in this review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Journal‐Published</b> </p> <p><b>Author /year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Registered on</b> </p> <p><b>Novartis Clinical Trial</b> </p> <p><b>Results Database</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Registered on</b> </p> <p><b>ClinicalTrials.gov</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CSR* received from EMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Request to</b> </p> <p><b>EMA was made on</b> </p> <p><b>November 15th 2015.</b> </p> <p><b>Weeks waited</b> </p> <p><b>to obtain CSR</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No journal publication</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT01237223</p> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EMA does NOT possess</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0076" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. ">Littlejohn 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00739973</p> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EMA does NOT possess</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0074" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. ">Kushiro 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT registered</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mar 11, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No journal publication</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00344110</p> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>May 23, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0060" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. ">Gradman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT registered</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jan 25, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0084" title="PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">Pool 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT FOUND</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT registered</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apr 12, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0094" title="VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">Villamil 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00219024</p> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apr 6, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0082" title="OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">Oh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00219128</p> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feb 20, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0089" title="SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">Schmieder 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00219154</p> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>May 27, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0083" title="OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">Oparil 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT registered</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>June 16, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0087" title="PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">Puig 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT registered</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EMA does NOT possess</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0093" title="VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">Villa 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00706134</p> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>December 22, 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> </tbody> </table> </div> <p>Two studies were not published in journals but were identified on the <a href="./references#CD007066-bbs2-0081" title="Novartis. Novartis Clinical Trials Databasehttps://www.novartisclinicaltrials.com/TrialConnectWeb/home.nov. ">Novartis Clinical Trial Results Database</a>. </p> <p>One published study <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a> was not found on the <a href="./references#CD007066-bbs2-0081" title="Novartis. Novartis Clinical Trials Databasehttps://www.novartisclinicaltrials.com/TrialConnectWeb/home.nov. ">Novartis Clinical Trial Results Database</a> (<a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>). </p> <p>Six studies, which are registered on the <a href="./references#CD007066-bbs2-0081" title="Novartis. Novartis Clinical Trials Databasehttps://www.novartisclinicaltrials.com/TrialConnectWeb/home.nov. ">Novartis Clinical Trial Results Database</a>, did not provide results (<a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>, <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>, <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>, <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>, <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>, and <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>). </p> <p>Five of the included studies are not registered on ClinicalTrials.gov web site ( <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>, <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>, <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>, <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>, <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>). </p> <p>Three studies are registered on ClinicalTrials.gov web site (<a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>, <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>, and <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>), but the results are not posted. </p> <p>We have received only partial clinical study reports (CSRs) as appendices and individual patient data were not included. We need to make separate specific requests to the European Medicines Agency (EMA) to obtain this information. </p> </section> <section id="CD007066-sec-0071"> <h4 class="title">Included studies</h4> <p>All 12 included studies were sponsored by the manufacturer (Novartis).</p> <p>The 12 included studies had a total of 7439 patients (placebo = 2319; aliskiren = 5120). The majority of included studies were randomized , double‐blind, parallel group multicentre studies of eight weeks duration. The exceptions include the three trials: <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> (13 weeks duration), <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a> (four weeks duration per dose), and <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> (three weeks duration per dose). </p> <p>Six studies (<a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>; <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>; <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>; <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>) included active treatment arms in addition to placebo, comparing arms of aliskiren, combination therapy with valsartan, hydrochlorothiazide (HCTZ), and the respective monotherapies. Details of each included study are provided in <a href="./references#CD007066-sec-0131" title="">Characteristics of included studies</a>. </p> <p>Following a one‐ to two‐week washout period from any prior antihypertensive medications, all studies had a two ‐to four‐week single‐blind placebo‐controlled run‐in period, followed by three to 13 weeks of randomized treatment. In most published studies, baseline mean sitting diastolic blood pressure (MSDBP) and mean sitting systolic blood pressure (MSSBP) were provided, but no endpoint MSDBP and MSSBP were provided. Consequently, comparisons were based on least square means (LSMs) and standard error (SE), which were converted to standard deviations (SDs). Only two published studies provided baseline and endpoint BP data (<a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> and <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>). The differences in the change in MSDBP and MSSBP in these two studies were similar to the LSMs provided. </p> <p>In five of the studies (<a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>; <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>; <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>), patients received aliskiren once daily 75 mg, 150 mg and 300 mg. </p> <p>In two studies (<a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>), patients received once daily aliskiren 150 mg, 300 mg or 600 mg. </p> <p>In <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>, patients received once daily aliskiren 150 mg and then increased it to 300 mg in all patients after four weeks. </p> <p>In <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>, study patients received aliskiren 150 mg, HCTZ 12.5 mg or placebo for three weeks and all patients were then force titrated to double the dose for an additional three weeks. After six weeks from the start of the study, the placebo group was given active treatment so only data from aliskiren 150 mg data at week three and aliskiren 300 mg data at week six have been included. </p> <p>In <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>, patients were randomized to aliskiren 150 mg, 300 mg and placebo monotherapy as well as several combination therapy groups for a duration of eight weeks. </p> <p>In <a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>, study patients were randomized to aliskiren 150 mg and placebo for a duration of eight weeks. </p> <p>In <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>, study patients were randomized to aliskiren 150 mg and placebo for a duration of eight weeks. </p> <section id="CD007066-sec-0072"> <h5 class="title">Population Characteristics</h5> <p>All studies had similar inclusion and exclusion criteria (see <a href="./references#CD007066-sec-0131" title="">Characteristics of included studies</a>). </p> <p><b>Inclusion criteria</b>: Patients were at least 18 years of age with mild‐to‐moderate essential hypertension defined as MSDBP &gt; 95 mm Hg and &lt; 110 mm Hg at baseline. Two studies (<a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> and <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>) were conducted in Japanese centres with only Asian adult patients (20 to 80 years of age for <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; 20 to 75 years of age for <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>). All 12 studies had similar SBP and DBP at baseline ranging from 152 mmHg to 160 mmHg for SBP and 90 mmHg to 100 mmHg DBP. Most studies had Caucasian patients, ranging from 61% to 99% of randomized patients. The mean age in all studies ranged from 52 to 56 years of age except in <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>. This study was conducted in elderly hypertensive patients ≥ 65 years of age; mean age of participants was 72 years. </p> <p><b>Exclusion criteria</b>: Patients were excluded if pregnant or breast feeding, had MSDBP &gt;110 mm Hg and/or MSSBP &gt; 180 mm Hg, had a history or evidence of secondary hypertension, type 1 or type 2 diabetes with poor glycaemic control, or any surgical or medical condition that might alter the absorption, distribution, metabolism or excretion of study drugs. Patients were also excluded if they had a history of severe cardiovascular, cerebrovascular, hepatic, or renal disease. </p> </section> <section id="CD007066-sec-0073"> <h5 class="title">Blood Pressure Measurements</h5> <p>The position of the patient during blood pressure measurement may affect the blood pressure lowering effect. When blood pressure measurement data was available in more than one position, data was extracted in accordance with the following order of preference: 1) sitting; 2) standing; and 3) supine. In all studies, MSSBP and MSDBP were available for baseline measurements, and LSMs and SE were available for end of treatment reductions in MSSBP and MSDBP. </p> <p>If blood pressure measurements were available at more than one time during the 24‐hour period, the trough measurement was used. Peak level is defined as within 12 hours of the dose and trough level is defined as between 12 and 24 hours. All studies reported trough MSSBP and MSDBP levels. </p> <p>In all studies, sitting blood pressure (BP) measurements were recorded at baseline and regular intervals throughout studies (for example, at weeks one, two, four, six and eight). As well, sitting BP was measured using a calibrated standard mercury sphygmomanometer or an alternative calibrated method, in accordance with the 1988 AHA Committee Report on Blood Pressure Determination. Sitting blood pressure was measured after the patient had rested in sitting position for at least five minutes. The measurement was repeated a total of three times at an interval of one to two minutes. The three values were averaged to obtain a mean sitting blood pressure. </p> <p>BP was measured at trough (24 + 3 hour post dose). At the first study visit, the patient's arm with the highest sitting DBP became the arm used for all subsequent readings in the study. At each study visit BP was measured three times at one‐ to two‐minute intervals, with the mean used as the BP for that visit. As well, one BP measurement was taken in standing position after the patient stood for two minutes. </p> </section> <section id="CD007066-sec-0074"> <h5 class="title">Power</h5> <p>In five studies (<a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>; <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>; <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>), sample size was calculated to ensure sufficient power for both a primary intention‐to‐treat (ITT) analysis and a per‐protocol analysis. The study assumed a dropout rate of 10% and a standard deviation of 8 mm Hg for MSDBP. The sample size provided a 90% power to detect a treatment difference of at least 3.5 mm Hg for pair‐wise comparisons at a two‐sided significance level of 0.05. </p> <p>In <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>, the sample size provided an 80% power to detect a 3.5 mm Hg in MSDBP. </p> <p>The study <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a> provided 90% power, and <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> provided 95% power, to detect a treatment difference of at least 2 mm Hg in MSDBP. </p> <p>In <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>, the sample size was calculated to provide at least 97% power to detect a difference of 5 mm Hg in MSSBP between at least one aliskiren dose and placebo. </p> <p>In <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>, the sample size provided an 90% power to detect a 3.3 mm Hg in MSDBP and a SD of 8 mmHg. </p> <p>The synopses of <a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> and <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> studies do not provide details of how sample size was calculated. </p> </section> <section id="CD007066-sec-0075"> <h5 class="title">Outcome Characteristics</h5> <p>The primary outcome of all studies was reduction in MSDBP.</p> <p>Secondary efficacy variables of the studies included the following.</p> <p> <ol id="CD007066-list-0007"> <li> <p>Mean reduction in MSSBP</p> </li> <li> <p>Diastolic responder rates (defined as DBP less than 90 mm Hg or equal to 10 mm Hg reduction in DBP) </p> </li> <li> <p>BP control rates (defined as a BP less than 140/90 mm Hg)</p> </li> <li> <p>Safety and tolerability of aliskiren</p> </li> <li> <p>Effects on plasma renin activity and renin concentration.</p> </li> </ol> </p> </section> </section> <section id="CD007066-sec-0076"> <h4 class="title">Excluded studies</h4> <p>Of the 46 articles retrieved for detail reading of study methodology, 31 studies did not meet our inclusion criteria and were excluded: two in 2008, eight in 2011 and 21 in 2017. The reasons for exclusion are reported in <a href="./references#CD007066-sec-0132" title="">Characteristics of excluded studies</a>. The main reasons form exclusion were lack of a parallel placebo control group or no aliskiren monotherapy treatment arm. </p> </section> </section> <section id="CD007066-sec-0077"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD007066-fig-0002">Figure 2</a> </p> <div class="figure" id="CD007066-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgments about each methodological quality item for each included study." data-id="CD007066-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgments about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD007066-sec-0078"> <h4 class="title">Allocation</h4> <section id="CD007066-sec-0079"> <h5 class="title">Random sequence generation (selection bias)</h5> <p>We considered 10 studies to have low risk of bias <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>; <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>; <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>; <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>; <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>; <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>; <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>), because they reported adequate sequence generation using computer‐generated random numbers and patients were assigned to treatment groups <i>via</i> central allocation or using validated interactive voice response system that automates random assignment. </p> <p>We considered two studies to have 'unclear' risk of bias:</p> <p> <ol id="CD007066-list-0008"> <li> <p>Study <a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>: random sequence generation was not reported within the clinical study synopses. Also, lack of access to their respective CSRs renders us unable to rate this level of bias. We have rated it as 'unclear' at this time. </p> </li> <li> <p>Study <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>: was rated to have unclear risk of bias as randomization was performed by Covance Inc. using validated system, however the detail of the method used was not reported in the CSR and we did not have access to the appendices for further details. </p> </li> </ol> </p> </section> <section id="CD007066-sec-0080"> <h5 class="title">Allocation concealment (selection bias)</h5> <p>We considered nine studies to have low risk of bias for allocation concealment as randomization data were kept strictly confidential until completion of the study and patients, investigators, collaborators and the sponsor were unaware of the treatment assignments throughout the study until the database was locked (<a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>; <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>; <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>; <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>; <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>; <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>). </p> <p>We considered three studies to have unclear risk of bias:</p> <p> <ol id="CD007066-list-0009"> <li> <p><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>: as method of allocation concealment was not described in the clinical synopsis. </p> </li> <li> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>: randomization number was provided along with a unique medication number for the packages of study drug to be dispensed. We did not have access to the appendices for more detail. </p> </li> <li> <p><a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>: method of allocation concealment was not described in the clinical synopsis. The CSR is not available with EMA. </p> </li> </ol> </p> </section> </section> <section id="CD007066-sec-0081"> <h4 class="title">Blinding</h4> <p>We considered 10 studies to have low risk of bias for blinding as the identity of the treatment was concealed from patients, investigators and staff performing the assessment by the use of drugs that were identical in packaging, labelling, appearance, odour and schedule of administration (<a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>; <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>; <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>; <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>; <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>; <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>; <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a> ). </p> <p>We considered two studies to have unclear risk of bias as blinding of outcome assessors was not described (<a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> and <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>). </p> <p> <ol id="CD007066-list-0010"> <li> <p>Study <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>: is described as double‐blind. In order to adequately blind the study, patients were required to take a total of three tablets and two capsules of study medication throughout the study. No further details are provided. </p> </li> <li> <p>Study <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>: aliskiren was supplied as capsule for two doses (75 mg and 150 mg) and as tablet for 300 mg dose and there was insufficient information to determine if blinding was successful. </p> </li> </ol> </p> </section> <section id="CD007066-sec-0082"> <h4 class="title">Incomplete outcome data</h4> <p>We considered four studies to have high risk of bias for incomplete outcome reporting because total withdrawal of randomized patients significantly differed in placebo and aliskiren treatment groups. Also last observation carried forward (LOCF) analysis was done for missing data at study endpoint. <a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>; <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>; <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>. </p> <p>We considered eight studies to have unclear risk of bias as reasons for withdrawal differed between placebo and treatment groups particularly due to unsatisfactory therapeutic effect. Also LOCF analysis was done for missing data at study endpoint (<a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>; <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>; <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>; <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>; <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>. </p> </section> <section id="CD007066-sec-0083"> <h4 class="title">Selective reporting</h4> <p>We meticulously looked for all possible studies conducted in various databases as well as the manufacturer's web site <a href="./references#CD007066-bbs2-0081" title="Novartis. Novartis Clinical Trials Databasehttps://www.novartisclinicaltrials.com/TrialConnectWeb/home.nov. ">Novartis Clinical Trial Results Database</a>, FDA web site <a href="./references#CD007066-bbs2-0092" title="FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna). http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm#data Last updated on19th January 2016. ">U.S. Food and Drug Administration 2016</a> and ClinicalTrials.gov and found reporting bias for two studies (<a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>; <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>), which had no journal publication but were listed on the manufacturer's web site. </p> <p>We considered all 12 studies to have unclear risk of selective reporting bias. Protocols and CSRs (without appendices) were available for nine included studies. Most primary and secondary outcomes in these studies were reported. However for outcomes such as pulse pressure and heart rate, data were available in appendices which were not provided within CSRs from EMA. For the remaining three studies, since protocols were not available, we were unable to determine selective reporting risk of bias. </p> </section> <section id="CD007066-sec-0084"> <h4 class="title">Other potential sources of bias</h4> <p>We considered all 12 studies to have high risk of other bias as they were sponsored by the manufacturer. Authors of six studies are employees of Novartis Pharmaceuticals Corporation and are therefore eligible for Novartis stock and stock options (<a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>; <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>; <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>; <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>). </p> <p>There was no description available with respect to the trialists' conflict of interest for three studies (<a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>; <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>; <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>). From the <a href="./references#CD007066-bbs2-0057" title="Center for drug evaluation and research. Tekturna (Aliskiren) Medical Review. FDA database March 5th 2007, issue Application number 21‐985:1‐283. ">FDA Medical Review 2007</a> the regulator comments that financial disclosure forms were obtained for <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>, <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>, <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>, and <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>, but the financial disclosure form for <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> was not obtained. Moreover, the returned forms identified "Grants, Honoraria, Travel Expenses" exceeding $25,000 for Study (Study identifier redacted in FDA medical review) and "Consultant, speaker" exceeding $25,000 for Study (Study identifier redacted in FDA medical review). The regulator comments that "the two potential conflicts of interest could not prejudice the results greatly even if there were overt manipulation" due to the fact that the study takes place over multiple centres with small percentages of total study participants, and the study is double‐blinded. </p> </section> </section> <section id="CD007066-sec-0085"> <h3 class="title" id="CD007066-sec-0085">Effects of interventions</h3> <p>See: <a href="./full#CD007066-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD007066-sec-0086"> <h4 class="title">Mean change from baseline of trough systolic blood pressure</h4> <p><b>See</b><a href="./full#CD007066-tbl-0001">summary of findings Table for the main comparison</a> </p> <p>Aliskiren monotherapy was superior to placebo in lowering mean sitting systolic blood pressure (MSSBP). The additional magnitude of blood pressure lowering minus the placebo effect can be seen in <a href="./references#CD007066-fig-0005" title="">Analysis 1.1</a>. </p> <p>Aliskiren 75 mg versus placebo (mean difference (MD) ‐2.97, 95% confidence interval (CI) ‐4.76 to ‐1.18; participants = 1100; studies = 5; I<sup>2</sup> = 0%); aliskiren 150 mg versus placebo (MD ‐5.95, 95% CI ‐6.85 to ‐5.06; participants = 3786; studies = 12; I<sup>2</sup> = 17%); aliskiren 300 mg versus placebo (MD ‐7.88, 95% CI ‐8.94 to ‐6.82; participants = 3009; studies = 10; I<sup>2</sup> = 22%); aliskiren 600 mg versus placebo (MD ‐11.35, 95% CI ‐14.43 to ‐8.27; participants = 393; studies = 2; I<sup>2</sup> = 0%) see <a href="#CD007066-fig-0003">Figure 3</a>. Quality of evidence was graded as moderate for 75 mg, 150 mg and 300 mg dose and as low for 600 mg dose. </p> <div class="figure" id="CD007066-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Aliskiren vs. placebo, outcome: 1.1 Systolic BP.Highly significant subgroup differences were observed therefore mean overall effect size across all doses is not shown. The number of placebo group patients are divided equally in dose ranging studies when more than one dose of aliskiren was used.CSPP100A2308 study the SBP reduction in the treatment and placebo group are reported from the CSR page 61.CSPP100A2405 study the SD for all treatment groups are calculated from SEM reported on page 7 in the CSR ." data-id="CD007066-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Aliskiren vs. placebo, outcome: 1.1 Systolic BP.</p> <p>Highly significant subgroup differences were observed therefore mean overall effect size across all doses is not shown. The number of placebo group patients are divided equally in dose ranging studies when more than one dose of aliskiren was used. </p> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> study the SBP reduction in the treatment and placebo group are reported from the CSR page 61. </p> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a> study the SD for all treatment groups are calculated from SEM reported on page 7 in the CSR . </p> </div> </div> </div> <p><b>Note:</b> Since there was highly significant subgroup differences between aliskiren 75 mg, 150 mg, 300 mg and 600 mg dose for MSSBP reduction (I<sup>2</sup> = 90%), effect size is only presented as subtotals for each dose and overall MSSBP reduction is not shown. The number of patients in the placebo group is divided between various aliskiren dose comparisons if the study used more than one dose of aliskiren as compared to placebo. </p> <p>There was no statistically significant heterogeneity observed for reduction in MSSBP for aliskiren 75 mg, 150 mg, 300 mg or the 600 mg dose. The I<sup>2</sup> was zero for the 75 mg and 600 mg doses. For aliskiren 150 mg, one unpublished study which had a low MSSBP reduction in the placebo group ( ‐2.0 mmHg in <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>) when removed from the analysis, reduced the I<sup>2</sup> from 17% to 0%. </p> <p>For aliskiren 300 mg, when two published studies, which had a low MSSBP reduction in the placebo group ( ‐2.9 mmHg in <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> and ‐3.8 mmHg in <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>) were removed from the analysis, the I<sup>2</sup> was reduced from 22% to 0%. Baseline MSSBPs were similar in all studies. </p> </section> <section id="CD007066-sec-0087"> <h4 class="title">Mean change from baseline of trough diastolic blood pressure</h4> <p><b>See</b><a href="./full#CD007066-tbl-0001">summary of findings Table for the main comparison</a> </p> <p>Aliskiren monotherapy was superior to placebo in lowering mean sitting diastolic blood pressure (MSDBP). The additional magnitude of blood pressure lowering minus the placebo effect can be seen in <a href="./references#CD007066-fig-0006" title="">Analysis 1.2</a>. </p> <p>Aliskiren 75 mg versus placebo (MD ‐2.05, 95% CI ‐3.13 to ‐0.96; participants = 1100; studies = 5; I<sup>2</sup> = 0%); aliskiren 150 mg versus placebo (MD ‐3.16, 95% CI ‐3.74 to ‐2.58; participants = 3783; studies = 12; I<sup>2</sup> = 47%); aliskiren 300 mg versus placebo (MD ‐4.49, 95% CI ‐5.17 to ‐3.82; participants = 3001; studies = 10; I<sup>2</sup> = 17%); aliskiren 600 mg versus placebo (MD ‐5.86, 95% CI ‐7.73 to ‐3.99; participants = 393; studies = 2; I<sup>2</sup> = 0%), see <a href="#CD007066-fig-0004">Figure 4</a>. Quality of evidence was graded as moderate for 75 mg, 150 mg and 300 mg dose, and as low for 600 mg dose. </p> <div class="figure" id="CD007066-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Aliskiren vs. placebo, outcome: 1.2 Diastolic BP.Highly significant subgroup differences were observed, therefore mean overall effect size across all doses is not shown. The number of placebo group patients are divided equally in dose ranging studys when more than one dose of aliskiren was used.CSPP100A2308 study the DBP reduction in the treatment and placebo group are reported from the CSR which differ from those reported in the published article. The previous version of this review used data from the published article.CSPP100A2405 study the SD for all treatment groups are calculated from SEM reported from the CSR on page 8." data-id="CD007066-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Aliskiren vs. placebo, outcome: 1.2 Diastolic BP.</p> <p>Highly significant subgroup differences were observed, therefore mean overall effect size across all doses is not shown. The number of placebo group patients are divided equally in dose ranging studys when more than one dose of aliskiren was used. </p> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> study the DBP reduction in the treatment and placebo group are reported from the CSR which differ from those reported in the published article. The previous version of this review used data from the published article. </p> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a> study the SD for all treatment groups are calculated from SEM reported from the CSR on page 8. </p> </div> </div> </div> <p><b>Note:</b> Since there was highly significant subgroup differences between aliskiren 75 mg, 150 mg, 300 mg and 600 mg dose for MSSBP reduction (I<sup>2</sup> = 86.6%), effect size is only presented as subtotals for each dose and overall MSDBP reduction is not shown. The number of patients in the placebo group is divided between various aliskiren dose comparisons if the study used more than one dose of aliskiren. </p> <p>There was no statistically significant heterogeneity observed for MSDBP for aliskiren 75 mg, and 600 mg dose. For aliskiren 150 mg, when one unpublished study which had a low MSDBP reduction in the placebo group (‐3.0 mmHg in <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>) was removed from the analysis, the I<sup>2</sup> was reduced from 47% to 0%. For aliskiren 300 mg , removing either <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> or <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>, which had a low MSDBP reduction in the placebo group ( ‐3.0 mmHg in <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> or ‐3.5 mmHg in <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>) from the analysis, reduced the I<sup>2</sup> from 4% to 0%. Baseline MSDBPs were similar in all studies. </p> </section> <section id="CD007066-sec-0088"> <h4 class="title">Comparing MSSBP and MSDBP reduction between aliskiren doses from the same study</h4> <p>Refer <a href="#CD007066-tbl-0007">Table 6</a> </p> <div class="table" id="CD007066-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparing MSSBP and MSDBP reduction between aliskiren doses from the same study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SBP WMD with 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DBP WMD with 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aliskiren 150 mg vs 75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.89 (‐3.16 to ‐0.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.80 (‐1.58 to ‐0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A<b>liskiren</b> 150 mg reduces SBP and DBP more than </p> <p>75 mg by 2/1 mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aliskiren 300 mg vs 75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.10 (‐6.79 to ‐3.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.49 (‐3.53 to ‐1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A<b>liskiren</b> 300 mg reduces SBP and DBP more than </p> <p>75 mg 5/3 mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aliskiren 300 mg vs 150 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.62 (‐3.38 to ‐1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.80 (‐2.28 to ‐1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A<b>liskiren</b> 300 mg reduces SBP and DBP more than </p> <p>150 mg 3/2 mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aliskiren 600 mg vs 150 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.40 (‐5.58 to ‐1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.20 (‐3.55 to ‐0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A<b>liskiren</b> 600 mg reduces SBP and DBP more than </p> <p>150 mg by 3/2mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aliskiren 600 mg vs 300 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.61 (‐2.78 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.68 (‐2.03 to 0.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference was observed</p> </td> </tr> </tbody> </table> </div> <p>Aliskiren 150 mg lowered MSSBP and MSSDP more than aliskiren 75 mg SBP: (MD ‐1.89, 95% CI ‐3.16 to ‐0.62; participants = 1651; studies = 5; I<sup>2</sup> = 23%) <a href="./references#CD007066-fig-0010" title="">Analysis 2.1</a> DBP: (MD ‐0.80, 95% CI ‐1.58 to ‐0.03; participants = 1651; studies = 5; I<sup>2</sup> = 0%) <a href="./references#CD007066-fig-0011" title="">Analysis 2.2</a> </p> <p>Aliskiren 300 mg lowered MSSBP and MSSDP more than aliskiren 75 mg SBP: (MD ‐5.10, 95% CI ‐6.79 to ‐3.40; participants = 904; studies = 3; I<sup>2</sup> = 21%) <a href="./references#CD007066-fig-0012" title="">Analysis 3.1</a> DBP: (MD ‐2.49, 95% CI ‐3.53 to ‐1.45; participants = 904; studies = 3; I<sup>2</sup> = 7%) <a href="./references#CD007066-fig-0013" title="">Analysis 3.2</a> </p> <p>Aliskiren 300 mg lowered MSSBP and MSSDP more than aliskiren 150 mg SBP: (MD ‐2.62, 95% CI ‐3.38 to ‐1.87; participants = 4405; studies = 10; I<sup>2</sup> = 51%) <a href="./references#CD007066-fig-0014" title="">Analysis 4.1</a> DBP: ((MD ‐1.80, 95% CI ‐2.28 to ‐1.32; participants = 4405; studies = 10; I<sup>2</sup> = 33%) <a href="./references#CD007066-fig-0015" title="">Analysis 4.2</a> </p> <p>Aliskiren 600 mg lowered MSSBP and MSSDP more than aliskiren 150 mg SBP: (MD ‐3.40, 95% CI ‐5.58 to ‐1.23; participants = 590; studies = 2; I<sup>2</sup> = 0%) <a href="./references#CD007066-fig-0016" title="">Analysis 5.1</a> DBP: (MD ‐2.20, 95% CI ‐3.55 to ‐0.85; participants = 590; studies = 2; I<sup>2</sup> = 0%) <a href="./references#CD007066-fig-0017" title="">Analysis 5.2</a> </p> <p>However, there were no differences in MSSBP (MD ‐0.61, 95% CI ‐2.78 to 1.56; participants = 592; studies = 2; I<sup>2</sup> = 0%) <a href="./references#CD007066-fig-0018" title="">Analysis 6.1</a> or MSDBP (MD ‐0.68, 95% CI ‐2.03 to 0.67; participants = 592; studies = 2; I<sup>2</sup> = 33%) <a href="./references#CD007066-fig-0019" title="">Analysis 6.2</a> for aliskiren 600 mg as compared to aliskiren 300 mg. </p> </section> <section id="CD007066-sec-0089"> <h4 class="title">Change in standard deviation</h4> <p>End of treatment standard deviation of SBP and DBP was similar in the placebo and aliskiren arms in the 12 included studies. Standard deviation of the change in MSSBP ranged from 11.2 to 14.2 in the aliskiren treatment arm as compared to 11.2 to 14.1 in the placebo treatment arm. Standard deviation of the change in MSDBP ranged from 7.7 to 8.8 in aliskiren treatment arm and from 7.7 to 8.7 in the placebo treatment arm. This is consistent with aliskiren having no effect on BP variability. </p> <p>Due to limited information available on standard error of the mean change in SD, this outcome has not been meta‐analyzed. </p> </section> <section id="CD007066-sec-0090"> <h4 class="title">Change in pulse pressure</h4> <p>Limited information on pulse pressure is available in the bodies of the clinical study reports (CSRs); rather, this outcome is reported within the CSR appendices to which we do not yet have access. </p> <p>However, <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> reports a reduction in pulse pressure at endpoint of ‐1.34, ‐3.5 and ‐3.91 for aliskiren 150 mg, 300 mg, and 600 mg, respectively versus +1.4 for placebo. At all study visits, aliskiren 600 mg produced the greatest reduction in sitting pulse pressure. </p> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a> reports pulse pressure increased (aliskiren 150 mg n = 1) as an adverse event, but the magnitude of this value is reported only in the appendices which are not yet accessible at this time. </p> <p>No journal‐published study reported on pulse pressure at both baseline or endpoint. Therefore due to very limited information available on change in pulse pressure, this data has not been meta‐analyzed. </p> </section> <section id="CD007066-sec-0091"> <h4 class="title">Change in heart rate</h4> <p>Five CSRs report on baseline sitting pulse rate but no data has been reported at the end of treatment. This data may be available in appendices which are not yet accessible at this time. </p> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> study reports baseline sitting pulse rate (SD) as 72.0 (9.80), 75.0 (9.73), 72.0 (9.68), and 73.8 (8.91) for placebo, aliskiren 75 mg, 150 mg, and 300 mg. </p> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> reports baseline sitting pulse as 72.8 (9.24), 72.9 (9.43), 72.2 (8.21) and 73.2 (8.51) for placebo, aliskiren 150 mg, 300 mg, and 600 mg, respectively. Also reported is baseline standing pulse rate as 76.1 (9.00), 76.3 (9.32), 76.0 (8.38) and 76.1 (8.95) for placebo, aliskiren 150 mg, 300 mg, and 600 mg, respectively. Aliskiren 600 mg produced a greater increase in trough sitting pulse than placebo at week eight (1.23 bpm versus ‐0.96 bpm; P = 0.0423). No other statistically significant differences between treatments were observed in either within‐treatment or between‐treatment analyses of trough sitting pulse at any time point. </p> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a> reports baseline sitting pulse as 71.6 (9.83), 72.0 (9.39), 72.3 (9.48) and 72.7 (9.22) for placebo, aliskiren 75 mg, aliskiren 150 mg, and aliskiren 300 mg, respectively. Also reported is baseline standing pulse rate as 76.3 (10.56), 77.0 (10.11), 76.4 (10.20, and 77.4 (10.02) for placebo, aliskiren 75 mg, aliskiren 150 mg, and aliskiren 300 mg respectively. Changes from baseline were minim al and generally similar across treatment groups. </p> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> reports average baseline sitting and standing pulse rate as 72.2 bpm and 75.6bpm, respectively (page 60 of CSR). Summary statistics for baseline average sitting and standing pulse are provided in appendices, but not yet ascertained for the randomized and per protocol population. </p> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a> reports baseline sitting pulse rate as 73.8 (9.32), 72.8 (9.00), 73.8 (9.07) and 73.3 (9.03) for placebo, aliskiren 75 mg, 150 mg, and 300 mg, respectively (page 67 of CSR). There were no clinically meaningful differences in mean change from baseline in sitting pulse. </p> <p>The journal‐published studies and clinical study synopses did not report on pulse rate. Therefore, due to very limited information available, these data have not been meta‐analyzed. </p> </section> <section id="CD007066-sec-0092"> <h4 class="title">Mortality</h4> <p>No deaths were reported in six studies during single‐blind, double‐blind or withdrawal period (<a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>; <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>; <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>; <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>; <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>. </p> <p>Refer to <a href="#CD007066-tbl-0008">Table 7</a> for detail information on cause of death in the following studies: </p> <div class="table" id="CD007066-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Mortality during single‐blind, double‐blind and withdrawal period in the 12 included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study identifier</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Single‐blind period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Double‐blind period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal period</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death in placebo group during observation period due to pancreatic carcinoma and metastases to liver. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death occurred in aliskiren 150 mg monotherapy on day 41 of the study, due to drug intoxication. The overdose was attributed to a psychiatric drug prescribed prior to start of the study, and a diagnosis of manic depressive psychosis was recorded. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death occurred in the placebo arm on day 16 from "natural causes".</p> <p>One death occurred in the valsartan 160 mg arm (day 26) as a result of motor vehicle accident. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death was reported in the Aliskiren/HCTZ 150/25 mg group due to thoracic trauma from a motor vehicle accident. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 death occurred in placebo run‐in phase. Patient hospitalized due to supraventricular tachycardia and abdominal pain and died due to stroke after discontinuing from the study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death occurred in the aliskiren/HCTZ 150/300 mg group from acute bronchopneumonia and associated sepsis during the 30‐day follow‐up period after discontinuing the study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 deaths reported.</p> <p>1 death in aliskiren group on day 41 due to myocardial infarction.</p> <p>1 death in valsartan group on day 13 and the cause was reported as hypertensive arteriosclerotic cardiovascular disease with SAE of sudden death. </p> <p>There were no deaths in placebo arm or combination therapy group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405:</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death occurred during the follow‐up period of the study from pneumonia leading to respiratory failure (day of death not provided). Further information regarding this death is described in the patient narratives of the CSR, which we do not have access to yet. Within the CSR body, the arm of the study that this participant belongs to has been redacted. </p> <p>In the 2008 FDA Medical Review report, a death due to colon cancer is reported as occurring within <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> (N = 1, aliskiren 300 mg). The medical review states "no other details were provided". For our comments on this please see <a href="#CD007066-sec-0100">Discussion</a>. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CSR:</b> clinical study report; <b>HTCZ:</b> hydrochlorothiazide; <b>SAE:</b> serious adverse event </p> </div> </div> <p>During the single‐blind period, there was one death in the placebo group in two studies, <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> and <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>. </p> <p>During the double‐blind period, there was one death in aliskiren 150 mg group in study <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; one death in placebo group in study <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; one death in aliskiren/HCTZ 150 mg/25 mg group in study <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>; and one death in aliskiren group in study <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>. </p> <p>During the withdrawal period there was one death in the aliskiren/HCTZ 150 mg/300 mg group in study <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> and one death in aliskiren 300 mg in study <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>. </p> <p>Due to the short duration of these studies and a very low incidence of death, the outcome of death was not meta analyzed. </p> </section> <section id="CD007066-sec-0093"> <h4 class="title">Non‐fatal serious adverse events (SAE)</h4> <p>During the double‐blind treatment period two SAEs were reported in the aliskiren monotherapy group in study <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; two SAEs in the aliskiren monotherapy group in study <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>; four SAEs in aliskiren 150 mg to 600 mg aliskiren monotherapy arms in study <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>; eight SAEs in aliskiren monotherapy arms in study <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>; four SAEs in aliskiren monotherapy arm in study <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>; and five SAEs in aliskiren monotherapy arm in study <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>. Refer to <a href="#CD007066-tbl-0009">Table 8</a> for detailed information. </p> <div class="table" id="CD007066-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Non‐fatal serious adverse events during wash out, single‐blind, double‐blind and withdrawal period</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study identifier</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Wash out period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Single blind period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Double blind period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal period</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No SAEs were reported in the aliskiren monotherapy group.</p> <p>2 in amlodipine 2.5 mg; 1 in amlodipine 5 mg; and 1 in aliskiren 150/amlodipine 5 mg combination arm (detail regarding SAE was not reported) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 SAEs reported.</p> <p>2 in placebo and 7 in other treatment groups (retinal detachment, abdominal mass, bronchitis, calculus ureteric, gastroenteritis, hand fracture, hydronephrosis, pneumonia, and cerebrovascular accident). </p> <p>None occurred in aliskiren 150 mg or 300 mg groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported 1 SAE in the single‐blind period ‐ infectious enterocolitis/dehydration (N = 1, 55M, placebo). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 SAEs in the double‐blind period:</p> <p>cerebral infarction (N = 1, 69F, placebo);</p> <p>acute myocardial infarction (N = 1, 58F, aliskiren 75 mg).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 SAEs reported.</p> <p>1 SAE in placebo due to myocardial infarction.</p> <p>The other in the losartan 50 mg group due to right medullary infarction.</p> <p>None in aliskiren 150 mg group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One in washout period ‐ transient Ischaemic attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two in the single‐blind run‐in phase ‐ anxiety; and diverticulitis and</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 SAEs in irbesartan group ‐ Intravertebral disc protrusion; and bipolar depression.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two in the withdrawal period in placebo group ‐ Left ventricular failure; and gout and infective arthritis). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported 6 SAE.</p> <p>1 bile duct cancer, 1 diverticulitis, 1 pregnancy, 1 mild melanorrhagia and gastric pain, 1 myocardial infarction, and 1 squamous cell carcinoma. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 SAEs reported.</p> <p>2 in Placebo: 1 due to natural cause and 1 due to myocardial infarction requiring hospitalization on day 46 resulting in study drug discontinuation. </p> <p>1 in aliskiren 75 mg on day 4 coronary artery disease requiring hospitalization resulting in study discontinuation. Patient required quadruple bypass surgery. </p> <p>1 in aliskiren 300 mg on day 42 pregnancy resulting in study discontinuation.</p> <p>1 in valsartan 160 mg on day 28 ‐ angioneurotic oedema resulting in study discontinuation, dyspnoea and chest pressure. </p> <p>Aliskiren 150 mg/valsartan 160 mg (N = 1, Day 29) motor vehicle accident requiring hospitalization; not discontinued from study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 in aliskiren 75 mg/valsartan 80 mg on day 3 post‐study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 SAE due to (lung cancer, fractured leg, angina and urinary tract infection)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 patients experienced at least 1 SAE in the monotherapy and combination therapy treatment groups. </p> <p>1 in A 75 mg ‐ due to renal colic; 1 in aliskiren 150 mg due to haemorrhagic diarrhoea; none in aliskiren 300 mg; 1 in HCTZ 6.25 mg due to neoplasm of skin; 3 in HCTZ 12.5 mg ‐ due to breast cancer, joint injury and pregnancy; 2 in HCTZ 25 mg due to deep vein thrombosis and lymphadenopathy; 5 in aliskiren 75 mg/HCTZ 12.5 mg due to (diplopia, IIIrd nerve paresis, mood disorder, phlebothrombosis, psychotic disorder, small intestinal obstruction and syncope); 4 in aliskiren 75 mg/HCTZ 25 mg due to (cerebral infarction, dysarthria, physical disability, pregnancy and renal colic); 2 in aliskiren 150 mg/ HCTZ 6.25 mg ulcerative colitis, pregnancy); 3 in aliskiren 150 mg/ HCTZ 12.5 mg (non‐cardiac chest pain, pregnancy, syncope); 2 in aliskiren 150 mg/ HCTZ 25 mg (lung neoplasm, road traffic accident); 2 in aliskiren 300 mg/ HCTZ 12.5 mg (diabetes mellitus, lung disorder); 1 in aliskiren 300 mg/HCTZ 25 mg (coronary artery disease). </p> <p>There were no SAEs in the placebo group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 SAEs reported during washout period ‐ 1 due to subarachnoid haemorrhage due to rupture of cerebral aneurysm on day 8; </p> <p>1 due to partial small bowel obstruction on day 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One SAE ‐ bladder carcinoma prior to randomization and before receiving double‐blind study drug. Patient was randomized to placebo but later discontinued due to unsatisfactory therapeutic effect; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 SAEs reported.</p> <p>1 SAE in aliskiren 150 mg on day 27‐ unstable angina and increased blood pressure;</p> <p>2 SAEs in aliskiren 300 mg ‐ hospitalization for acute appendicitis on day 34; hospitalization for depression on day 51; </p> <p>1 SAE in aliskiren 600 mg of hospitalization for pain/bodily injury on day 35.</p> <p>No SAE reported in the placebo group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One SAE was reported during withdrawal period in aliskiren 150 mg of serious venous occlusion and thrombosis of the right eye on day 8 withdrawal period). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> </p> <p>data at week 3 and week 6 not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During 26 weeks double‐blind treatment period</p> <p>19 SAEs reported. 10 in aliskiren group and 9 in HCTZ group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 SAEs reported.</p> <p>5 in placebo group ‐ atrial flutter, cerebrovascular accident, headache, hypertension, hypertensive crisis and ventricular tachycardia); </p> <p>8 in aliskiren group ‐ 1 gastritis, 1 grand mal convulsions, 1 intestinal poly, 2 myocardial infarction, 1 non‐cardiac chest pain, 1 peripheral vascular disease, 1 acute renal failure); </p> <p>6 in valsartan group ‐ 1 angina pectoris, 1 arteriosclerosis, 1 breast cancer, 1 bronchitis, 1 COPD, 1 facial paresis, 1 ovarian cancer, 1 pneumonia, 1 pulmonary oedema); </p> <p>3 in aliskiren/valsartan group ‐ 1 aortic aneurysm, 1 intravertebral disc protrusion, 1 prostate cancer and 1 thyroidectomy). </p> <p>The FDA medical review (2007) also reported two cases of renal carcinoma occurred (N = 1, placebo, day 20 post‐study; N = 1, aliskiren, day 44 post‐study). For our comments on this, please see <a href="#CD007066-sec-0100">Discussion</a>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 patients had serious AEs during the washout and placebo run‐in periods (detail of which are not provided). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 SAE was reported in aliskiren 75 mg group ‐ cardiac chest pain;</p> <p>2 in aliskiren 150 mg group ‐ rectal bleeding due to anal ulcer and episode of secondary anaemia; basal cell carcinoma; </p> <p>1 in the 300 mg group ‐TIA with concomitant nausea and dyspnoea; and</p> <p>2 in the placebo group ‐ prostate cancer; accelerated hypertension with left facial numbness. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405:</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported 2 SAEs in the washout period; Detail not provided in CSR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Three in the single‐blind placebo run‐in period. Detail not provided in CSR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 SAEs were reported.</p> <p>2 in aliskiren 75 mg group ‐ erysipelas (skin infection) and osteoarthritis;</p> <p>3 in aliskiren 150 mg group ‐ severe glaucoma; moderate haemorrhoids; and mild hemorrhagic stroke; </p> <p>none in aliskiren 300 mg group; and</p> <p>1 in the placebo group ‐ vertigo, wrist fracture, concussion, and head contusion subsequent to a fall. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>COPD:</b> chronic obstructive pulmonary disease; <b>CSR:</b> clinical study report; <b>HTCZ:</b> hydrochlorothiazide; <b>SAE:</b> serious adverse event; <b>TIA:</b> transient ischaemic attack </p> </div> </div> <p>In addition, the <a href="./references#CD007066-bbs2-0057" title="Center for drug evaluation and research. Tekturna (Aliskiren) Medical Review. FDA database March 5th 2007, issue Application number 21‐985:1‐283. ">FDA Medical Review 2007</a> reports further details for the following studies. </p> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> : The FDA medical review reports events of cancer in aliskiren monotherapy arms, and lists two SAEs of rectal cancer (n = 1, in 59 Asian women, aliskiren 75 mg, day 75) and (n = 1, in 54 Asian men, aliskiren 75 mg, day 330). However, the study identifiers within the FDA medical review have been redacted. </p> <p>The clinical study synopsis for CSR 1202, an open‐label, extension study of <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>, lists two events of rectal cancer as reasons for study discontinuation (n = 1, aliskiren monotherapy; n = 1, aliskiren + diuretic), and the corresponding journal‐published study <a href="./references#CD007066-bbs2-0074" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. ">Kushiro 2006</a> also reports two events of rectal cancer, but does not report the arm of the study in which they occurred, and states "these were considered by the investigators to be present at the commencement of the study." Provided that the regulator reviewed only one study of Japanese participants (<a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>), and given the rectal cancer outcomes reported in <a href="./references#CD007066-bbs2-0074" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. ">Kushiro 2006</a>, we believe the SAEs pertain to the extension study of <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>. Unfortunately, due to the redactions in the FDA medical review and the lack of access to the unabridged CRSs (including patient narratives), we cannot confirm this. These SAEs are not described in the body of CSR 1201. </p> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>: The FDA Medical Review (2007) reported a case of an isolated seizure (n = 1, aliskiren, day 3). The participant was hospitalized with a diagnosis of grand mal seizure, despite no previous history of seizures. The regulator notes that imaging studies and EEG were not provided in the initial report provided. The FDA medical review (2007) also reported two cases of renal carcinoma occurred (n = 1, placebo, day 20 post‐study; n = 1, aliskiren, day 44 post‐study). For our comments on this, please see <a href="#CD007066-sec-0100">Discussion</a>. </p> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>: The three aliskiren monotherapy groups each had one patient with SAEs. Though these are reported within the CSR body, they are described in greater detail in the 2007 FDA medical review: renal colic necessitating hospitalization (n = 1 in 44 men, aliskiren 75 mg, day 19); hematuria and urinary retention necessitating catheterization to unblock a clot (n = 1 in 80 men, aliskiren 150 mg, day 19); and rectal bleeding from a stenosing tumour, which was confirmed as adenocarcinoma (n = 1 in 69 men, aliskiren 300 mg, day 46) aliskiren 300 mg group). Study medication was not discontinued. We note that <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> reports this latter SAE only as "hemorrhagic diarrhoea". This explains the reason that the FDA medical review (2007) reports an event of colon cancer (n = 1 in 69 men, aliskiren 300 mg, day 59), though this event is not reported in <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>. It is unfortunate that we cannot confirm at this time whether this patient is the same patient or different from the reported event of death due to colon cancer within the 2008 FDA medical review. </p> <p>During the single‐blind period, the FDA medical review (2007) reports chest pain and headache (n = 1 in 42 women, aliskiren 300 mg, day 25), which developed into cardiac ischaemia with diagnosis based on ST depression in V3‐5 not present on the baseline ECG after one dose of blinded study medication. The study drug was discontinued. The patient was subsequently hospitalized for unstable angina. HCTZ monotherapy had oneSAE in the 6.25 mg group; three SAEs in the 12.5 mg group and two SAEs in the 25 mg group. An event of colon cancer is reported in the FDA medical review (2007) (n = 1, HCTZ 25 mg, day 57), though this is not described in <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>. Combination treatment groups had a total of 19 SAEs. The FDA medical review (2007) reports a stroke (n = 1, in 67 men, aliskiren 150 mg/HCTZ 6.25 mg) 19 days after the participant discontinued from the study. This SAE is not described within the body of <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>. </p> </section> <section id="CD007066-sec-0094"> <h4 class="title">Any adverse event</h4> <p>Reporting of total adverse events varies between studies since journal‐published studies did not report details regarding adverse events. In the 12 included studies, total adverse events in aliskiren groups ranged from 7.8% to 55% and from 21% to 50% in the placebo group. The most frequent events being ‐ headache ‐ ranged from 1.7% to 7.8% in aliskiren treatment groups and from 3.4 % to 13.5% in the placebo group; diarrhoea ‐ ranged from 0.8% to 11.4% in aliskiren treatment groups and from 0.5 % to 1.7% in the placebo group; dizziness ‐ ranged from 1.2% to 5.3% in aliskiren treatment groups and from 2% to 4.2% in the placebo group; and fatigue ‐ ranged from 0.8% to 3.8% in aliskiren treatment groups and from 1% to 3.1% in the placebo group. Refer <a href="#CD007066-tbl-0010">Table 9</a> for additional details. </p> <div class="table" id="CD007066-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Total adverse events during double blind treatment period</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study Identifier</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs and Common AEs as reported in the corresponding available CSR</b> </p> <p><b>A = Aliskiren; P = Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A150 =15(7.8%); A 300 = 18(8.9%) and P = 22(7.7%) </p> <p><b>Headache:</b> A150 =13( 6.7%); A 300 =15(7.4%) and P = 20(10.1%) </p> <p><b>Periphaeral edema:</b> A150 = 2(1.0%); A 300 = 3(1.5%) and P = 2(1%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A150 = 40.1%; A 300 = 46.7%; A 600 = 52.4%; P = 43% </p> <p><b>Headache</b>: A150 = 12(7%); A300 = 13(7.7%); A600 = 9(5.4%); P = 16(9.7%) </p> <p><b>Nasopharyngitis</b>: A 150 = 5(2.9%); A 300 = 6(3.6%); A 600 = 3(1.8%); P = 10(6.1%) </p> <p><b>Dizziness</b>: A 150 = 2(1.2%); A 300 = 9(5.3%); A 600 = 5(3%); P = 7(4.2%) </p> <p><b>Diarrhoea</b>:A 150 = 2(1.2%); A 300 = 3(1.8%); A 600 = 19 (11.4%); P = 2(1.2%) </p> <p><b>Nausea</b>: A 150 = 2(1.2%); A 300 = 3(1.8%); A 600 = 0%; P = 4(2.4%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A75 = 61(53%); A150 = 58(51.8%); A 300 = 62(54.9%); P = 58(50.4)% </p> <p><b>Headache:</b> A75 = 3(2.6%); A 150 = 3(2.7%); A 300 = 6 (5.3%) and P = 4(3.5%) </p> <p><b>Nasopharyngitis</b>:A75 = 24(20.9%); A150 = 20(17.9%); A300 = 20(17.7%); P = 16(13.9%) </p> <p><b>Back pain</b>:A75 = 2(1.7%); A150 = 0%; A300 = 0% and P = 0% </p> <p><b>Diarrhoea:</b> A75 = 1(0.9%); A150 = 1(0.9%); A300 = 4(3.5%) and P = 1(0.9%) </p> <p><b>Vertigo:</b> A75 =0%; A150 = 0%); A300 = 1(0.9%) and P = 2(1.7%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs:</b> A150 = 152(50.3%), P = 66(42.3%) </p> <p><b>Nasopharyngitis:</b> A150 = 48(15.9%), P = 13(8.3%) </p> <p><b>Headache:</b> A150 = 9(3.0%), P = 6(3.8%) </p> <p><b>Occult blood positive:</b> A150 = 9 (3.0%), P =5 (3.2%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs:</b> A150 = 127 (26.8%); A300 = 130 (36.2%); A600 = 43 (33.1%); P = 32 (32.1%) </p> <p><b>Headache:</b> A150 = 3 (2.4%); A300 = 8 (6.2%); A600 = 6 (4.6%); P = 7 (5.3%) </p> <p><b>Diarrhoea:</b> A150 = 2 (1.6%); A300 = 1 (0.8%); A600 = 9 (6.9%); P = 2 (1.5%) </p> <p><b>Dizziness:</b> A150 = 2 (1.6%); A300 = 4 (3.1%); A600 = 3 (2.3%); P = 5 (3.8%) </p> <p><b>Fatigue:</b> A150 = 1 (0.8%); A300 = 5 (3.8%); A600 = 2 (1.5%); P = 4 (3.1%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A75 = 63(35.2%); A150 = 59(33.1%); A300 = 50(28.6%) and P = 57(32.2%) </p> <p><b>Headache</b>: A75 = 15(8.4%); A150 = 9(5.1%;) A 300 = 7(4.0%) and P = 15(8.5%) </p> <p><b>Fatigue</b>: A75 = 7(3.9%); A150 = 4(2.2%;) A 300 = 4(2.3%) and P = 4(2.3%) </p> <p><b>Back pai</b>n: A75 = 2(1.1%); A150 = 4(202%;) A 300 = 3(1.7%) and P = 2(1.1%) </p> <p><b>Diarrhoea</b>: A75 = 2(1.1%); A150 = 1(0.6%;) A 300 = 5(2.9%) and P = 3(1.7%) </p> <p><b>Dizziness:</b> A75 = 4(2.2%); A150 = 4(2.2%;) A 300 = 3(1.7%) and P = 2(1.1%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs:</b> A75 = 69(37.5%); A150 = 69(37.3%); A300 = 71 (39.2%); P = 85(44%) </p> <p><b>Headache</b>: A75 = 13(7.1%); A 150 = 13(7%); A 300 = 10 (5.5%); P = 26 (13.5%) </p> <p><b>Nasopharyngitis:</b> A75 = 9( 4.9%); A150 = 5(2.7%;) A300 = 3 (1.7%); P = 10 (5.2%) </p> <p><b>Diarrhoea</b>: A75 = 3(1.6%); A150 = 3(1.6%); A300 = 4(2.2%); P = 1(0.5%) </p> <p><b>Cough</b>: A75 = 1(0.5%); A150 = 2(1.1%); A300 = 1(0.6%); P = 1(0.5%) </p> <p><b>Dizziness</b>: A75 = 1(0.5%); A150 = 1(0.5%); A300 = 3(1.7%); P = 2(1.0%) </p> <p><b>Peripheral edema:</b> A75 = 4(2.2%); A150 = 3(1.6%); A300 = 2(1.1%); P = 1(0.5%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A150 = 40.1%; A 300 = 46.7%; A 600 = 52.4%; P = 43% </p> <p><b>Headache</b>: A150 = 12(7%); A300 = 13(7.7%); A600 = 9(5.4%); P = 16(9.7%) </p> <p><b>Nasopharyngitis</b>: A 150 = 5(2.9%); A 300 = 6(3.6%); A 600 = 3(1.8%); P = 10(6.1%) </p> <p><b>Dizziness</b>: A 150 = 2(1.2%); A 300 = 9(5.3%); A 600 = 5(3%); P = 7(4.2%) </p> <p><b>Diarrhoea</b>: A 150 = 2(1.2%); A 300 = 3(1.8%); A 600 = 19 (11.4%); P = 2(1.2%) </p> <p><b>Nausea</b>: A 150 =2 (1.2%); A 300 = 3(1.8%); A 600 =0%; P = 4(2.4%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b> at 6 weeks : A 26.4%; P = 28.5% (numbers not reported) </p> <p><b>Other AE</b> were not reported at week 6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs:</b> A150 to 300 = 149(34%) and P = 168(37%) </p> <p><b>Headach</b>e: A150 to 300 = 14(3.2%); P = 41(9%) </p> <p><b>Diarrhoea*</b>: A150 to 300 = 2.3%; P = not reported </p> <p><b>Nasopharyngitis</b>: A150 to 300 = 16(3.7%) ; P = 9(2%) </p> <p><b>Dizziness:</b> A 150 to 300 = 8(1.8%) ; P = 9(2%) </p> <p><b>Fatigue</b>:A 150 to 300 = 4(0.9%) ; P = 5(1.1%) </p> <p><b>Nausea</b>: A 150 to 300 = 6(1.4%) ; P = 11(2.4%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs:</b> A75 = 57(37.3%); A150 = 59(34.7%); A300 = 56(35.4%); P = 60(37.5%) </p> <p><b>Headache:</b> A75 = 12(7.8%); A150 = 7(4.1%); A300 = 10(6.3%) and P = 9(5.6%) </p> <p><b>Nasopharyngitis</b>: A75 = 2(1.3%); A150 = 2(1.2%); A300 = 5(3.2%) and P = 3(1.9%) </p> <p><b>Diarrhoea</b>: A75 = 7(4.6%); A150 = 2(1.2%); A300 = 1(0.6%) and P = 1(0.6%) </p> <p><b>Cough</b>: A75 = 1(0.7%); A150 = 4(2.4%); A300 = 1(0.6%) and P = 3(1.9%) </p> <p><b>Dizziness</b>: A75 = 1(0.7%); A150 = 5(2.9%); A300 = 1(0.6%) and P = 3(1.9%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405:</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A75 = 36(18.8%); A150 = 41(21.7%); A300 = 36(19.1%); P = 39(21.0%) </p> <p><b>Headache</b>: A75 = 4(2.1%);A150 = 2(1.1%); A300 = 1(1.1%); P = 4(2.1%) </p> <p><b>Influenza:</b> A75 = 1(0.5%); A150 = 4(2.1%); A300 = 1(1.1%); P = 1(0.5%) </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD007066-sec-0095"> <h4 class="title">Withdrawals due to adverse events</h4> <p>Withdrawals due to adverse effects between placebo and aliskiren at 75 mg, 300 mg and 600 mg dose did not differ (see <a href="./references#CD007066-fig-0007" title="">Analysis 1.3</a>). Aliskiren 75 mg versus placebo ‐ (RR 0.59, 95% CI 0.33 to 1.07; participants = 1653; studies = 5; I<sup>2</sup> = 0%); aliskiren 300 mg versus placebo ‐ (RR 0.70, 95% CI 0.47 to 1.03; participants = 4216; studies = 10; I<sup>2</sup> = 0%); and aliskiren 600 mg versus placebo ‐ (RR 0.56, 95% CI 0.19 to 1.64; participants = 592; studies = 2; I<sup>2</sup> = 0%). </p> <p>Compared to aliskiren 150 mg group, withdrawals due to adverse effects were greater in the placebo group mostly due to lack of therapeutic effect. Aliskiren 150 mg versus placebo ‐ (RR 0.46, 95% CI 0.30 to 0.71; participants = 3421; studies = 10; I<sup>2</sup> = 16%). <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> was not included in this comparison as the authors only report a combined total withdrawal rate n = 22 (3.9%) for both aliskiren and placebo treatment groups. </p> <p>For withdrawals due to adverse effects, there was no statistically significant heterogeneity at 75 mg, 150 mg, 300 mg or 600 mg dose. For 75 mg, 300 mg and 600 mg dose, the I<sup>2</sup> was 0%. For the 150 mg dose, when <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> was removed from the analyses, the I<sup>2</sup> was reduced from 16% to 0%. The reason for heterogeneity could not be determined. </p> <p>Refer to <a href="#CD007066-tbl-0011">Table 10</a> for detail regarding reasons for withdrawal from included studies. </p> <div class="table" id="CD007066-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Listing reasons for withdrawal due to adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study Identifier</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for increased withdrawal due to adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant adverse events occurred for N = 7 patients, leading to discontinuation from study, as described below. </p> <p> <ul id="CD007066-list-0011"> <li> <p>Placebo (N = 3): moderately elevated blood pressure (N = 1); moderate rotary vertigo and moderately elevated blood pressure (N = 1); cerebral infarction (N = 1); aliskiren 75 mg (N = 1): acute myocardial infarction (N = 1). </p> </li> <li> <p>Aliskiren 150 mg (N = 1): moderately elevated blood pressure (N = 1); aliskiren 300m g (N = 2); moderately elevated blood pressure (N = 1; drug eruption (N = 1). Adverse events suspected to be study drug‐related occurred in N = 5 patients. These events improved or resolved upon discontinuation of study drug. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD007066-list-0012"> <li> <p>Placebo = 7(4.5%): blood pressure increased (N = 3, 1.9%); headache (N =1, 0.6%); SBP increased (N = 1, 0.6%); gastroenteritis (N = 1, 0.6%); myocardial infarction (N = 1, 0.6%). Also, 6 (3.8%) patients withdrew due to abnormal test procedure results. </p> </li> <li> <p>Aliskiren 150 mg = 5 (1.7%); 5 (1.7%): joint pain (N =1, 0.3%); blood pressure increased (N =1, 0.3%); dizziness (N =1, 0.3%); head discomfort (N =1, 0.3%); headache (N = 1, 0.3%); and nausea (N =1, 0.3%). Also 5(1.7%) patients withdrew due to abnormal test procedure results. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A total of N = 18 patients discontinued from the study due to AEs. It was suspected that 2/3 of these discontinuations were for reasons drug‐related. Headaches resulted in the discontinuation for N = 3 patients. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most frequent reasons for 12 discontinuations are: fatigue (N = 5, 0.4%), headache (N = 3, 0.3%), diarrhoea (N = 2, 0.2%), and peripheral oedema (N = 2, 0.2%). </p> <p>Reasons for 14 discontinuations from AE (safety population).</p> <p> <ul id="CD007066-list-0013"> <li> <p>Placebo (N = 6, 3.4): myocardial infarction (N = 1, 0.6%); tachycardia (N = 1, 0.6%); diarrhoea (N = 1, 0.6%); fatigue (N = 1; 0.6%), peripheral oedema (N = 1, 0.6%); sudden death (N = 1, 0.6%); headache (N = 1, 0.6%). </p> </li> <li> <p>Aliskiren 75 mg (N = 5): coronary artery disease (N = 1, 0.6%); abdominal pain (N = 1, 0.6%); diarrhoea (N = 1, 0.6%); oedema (N = 1, 0.6%); headache (N = 1, 0.6%); syncope (N = 1, 0.6%); dermatitis bullous (N = 1, 0.6%); eczema (N = 1, 0.6%). </p> </li> <li> <p>Aliskiren 150 mg (N = 3, 1.7%): fatigue (N = 1, 0.6%); blood creatine phosphokinase increased (N = 1, 0.6%); pulse pressure increased (N = 1, 0.6%); migraine (N = 1, 0.6%); cold sweat (N = 1, 0.6%). </p> </li> </ul> </p> <p>The FDA medical review reports facial oedema (N = 1, 0.6%) that appears to be angioedema, resulting in discontinuation from study; however, this is not reported in CSR 2203. </p> <p> <ul id="CD007066-list-0014"> <li> <p>Aliskiren 300 mg (N = 3, 1.7%): vertigo (N = 1, 0.6%); influenza‐like illness (N = 1, 0.6%); flank pain (N = 1, 0.6%); pregnancy (N = 1, 0.6%). </p> </li> <li> <p>Additionally, in the aliskiren 150 mg arm, discontinuation from study occurred for (N = 1, 0.6%) abnormal laboratory values. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The range of AEs resulting in study discontinuation is 0% is the aliskiren 150 mg arm of the study to 4.4% in the aliskiren 300 mg arm (N = 7). The most frequent AE resulting in study discontinuation is headache (N = 12, 0.4%). </p> <p>Reasons for discontinuations from adverse events ‐ N = 62 (2.2%).</p> <p> <ul id="CD007066-list-0015"> <li> <p>Placebo (N = 7, 3.6%): blood pressure increased (N = 1, 0.5%; depression (N = 1, 0.5%); dizziness (N = 1, 0.5%); eye pruritis (N = 1, 0.5%); gastritis (N = 1, 0.5%); insomnia (N = 1, 0.5%): lacrimation increased (N = 1, 0.5%); tinnitus (N = 1, 0.5%). </p> </li> <li> <p>Aliskiren 75 mg (N = 1, 0.5%): dizziness (N = 1, 0.5%); nausea (N = 1, 0.5%).</p> </li> <li> <p>Aliskiren 150 mg (N = 0).</p> </li> <li> <p>Aliskiren 300 mg (N = 8, 4.4%): angina pectoris (N = 1, 0.6%); asthenia (N = 2, 1.1%); cough (N = 1, 0.6%); dizziness (N = 1, 0.6%); peripheral oedema (N = 1, 0.6%); emotional disorder (N = 1, 0.6%); fatigue (N = 1, 0.6%); headache (N = 1, 0.6%). </p> </li> </ul> </p> <p>Additionally four patients discontinued from the study due to abnormal laboratory values. </p> <p> <ul id="CD007066-list-0016"> <li> <p>Placebo (N = 1,Day 43): asymptomatic low white blood cell count.</p> </li> <li> <p>Aliskiren 75 mg (N = 1, Day 15): abnormal ranges found for haematology and chemistry parameters. </p> </li> <li> <p>Aliskiren 150 mg (N = 1, Day 6): elevated cholesterol and liver enzymes.</p> </li> <li> <p>Aliskiren/HCTZ 150 25 mg/25 mg (N=1, Day 9): elevated cholesterol, BUN, uric acid.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most frequent reasons for 9 discontinuation from study: headache (N = 4), dizziness (N = 3), and diarrhoea (N = 2). </p> <p>Reasons for discontinuations from AE (safety population).</p> <p> <ul id="CD007066-list-0017"> <li> <p>Headache (placebo: N = 4); dizziness (placebo; N = 2; aliskiren 300 mg; 1), diarrhoea (placebo: N = 1; aliskiren 600 mg: N = 1); increased blood pressure (1 in placebo group); duodenal ulcer (placebo: N = 1); hypotension (placebo: N = 1); lethargy (placebo: N = 1); muscle spasm (placebo: N = 1); nausea (placebo: N = 1); and urticaria (placebo: N = 1); flatulence (aliskiren 600 mg: N = 1); altered mood (aliskiren 300 mg: N = 1); rash (aliskiren 300 mg: N = 1); and sense of oppression (aliskiren 150 mg: N = 1). </p> </li> <li> <p>No patients were discontinued for abnormal laboratory values.</p> </li> </ul> </p> <p>We question that a participant withdrew for the reason specified as "unsatisfactory effect" as opposed to being categorized as a discontinuation from an SAE as the event necessitated hospitalization. On Day 27 in <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>, the participant (N = 1, 64F, aliskiren 150 mg) was hospitalized for unstable angina and increased blood pressure. The unstable angina was treated with concomitant medication and her condition resolved within 3 days. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We do not have data at week 3 and week 6 for this study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The range of AEs resulting in study discontinuation is 8 (1.8%) is the aliskiren arm; 8 (2.6%) in valsartan arm; 6 (1.3%) in aliskiren/valsartan combination arm; and 11 (2.4%) in the placebo arm. </p> <p>Reasons for discontinuations from adverse events ‐ N = 37 (2%).</p> <p> <ul id="CD007066-list-0018"> <li> <p>Placebo (N = 11, 2.4%): headache (N = 4, 0.9%); nausea (N = 1, 0.2%); dyspnoea (N = 1, 0.2%); atrial flutter (N = 1, 0.2%); dizziness (N = 1, 0.2%); epistaxis (N = 1, 0.2%): hypertension (N = 1, 0.2%); hypertensive crisis (N = 1, 0.2%); peripheral oedema (N = 1, 0.2%). </p> </li> </ul> <ul id="CD007066-list-0019"> <li> <p>Aliskiren = 8 (1.8%): blood pressure increased (N =1, 0.2%); gastritis (N =1, 0.2%); grand mal convulsion (N = 1, 0.2%); headache (N = 1, 0.2%); myocardial infarction (N = 2, 0.5%); non‐cardiac chest pain (N = 2, 0.5%); acute renal failure (N = 1, 0.2%). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aliskiren 75 mg = 3 (2.0%); aliskiren 150 mg = 5 (2.9%); aliskiren 300 mg = 4(2.5%) . </p> <p>Placebo = 4 (2.5%). Reasons for withdrawal were not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405:</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reasons for 18 discontinuations from AE (safety population)</p> <p> <ul id="CD007066-list-0020"> <li> <p>Placebo (N = 7, 3.8%): hypertension (N = 5, 2.7%); hypertensive crisis (N = 1, 0.5%); gastroenteritis (N = 1, 0.5%). </p> </li> <li> <p>Aliskiren 75 mg (N = 7, 3.7%): hypertension (N = 1, 0.5%); headache (N = 1, 0.5%); dizziness (N = 2, 1.0%); hypertensive crisis (N = 1, 0.5%); dyspepsia (N = 1, 0.5%); nausea (N = 1, 0.5%). </p> </li> <li> <p>Aliskiren 150 mg (N = 1); hypertension (N = 1).</p> </li> <li> <p>Aliskiren 300 mg (N = 3): hypertension (N = 2, 1.1%),;headache (N = 1, 0.5%); vertigo (N = 1, 0.5%) </p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD007066-sec-0096"> <h4 class="title">Specific adverse events</h4> <p>Dry cough as an adverse event was reported in the following five studies: refer <a href="./references#CD007066-fig-0008" title="">Analysis 1.4</a>. </p> <p> <ol id="CD007066-list-0021"> <li> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>: aliskiren 150 mg n = 1 (0.9%) </p> </li> <li> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>: placebo n = 1 (0.8%), aliskiren 150 mg n = 2 (1.6%), aliskiren 300 mg n = 4 (3.1%) </p> </li> <li> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>: placebo n = 2 (1.1%), aliskiren 75 mg n = 2 (1.1%), aliskiren 150 mg n = 5 (2.8%), aliskiren 300 mg n = 1 (0.6%) </p> </li> <li> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>: aliskiren 300 mg n = 1 (0.6%) </p> </li> <li> <p><a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>: placebo: n = 3 (1.9%), aliskiren 75 mg n = 1 (0.7%), aliskiren 150 mg: n = 4 (2.4%), aliskiren 300 mg: n = 1 (0.6%). </p> </li> </ol> </p> <p>Cough was not reported in the other seven studies (<a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>; <a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a>; <a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>;<a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>; <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>; and <a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a>). </p> <p>Based on five studies in 2886 patients, the incidence of cough did not differ between aliskiren (75 mg to 600 mg dose) as compared to placebo (RR 1.14, 95% CI 0.49 to 2.64; I<sup>2</sup> = 0%). </p> <section id="CD007066-sec-0097"> <h5 class="title">Diarrhoea</h5> <p>Refer to <a href="./references#CD007066-fig-0009" title="">Analysis 1.5</a> and to <a href="./full#CD007066-tbl-0001">summary of findings Table for the main comparison</a> graded as low‐quality evidence. </p> <p>Aliskiren at 75 mg to 300 mg dose as compared to placebo showed a trend towards increase in incidence of diarrhoea. However at a dose of 600 mg, a substantial increase was observed (from 14 per 1000 in placebo group to 95 per 1000 in aliskiren 600 mg group): </p> <p> <ol id="CD007066-list-0022"> <li> <p>aliskiren 75 mg: (RR 2.21, 95% CI 0.85 to 5.76; participants = 1276; studies = 4; I<sup>2</sup> = 13%); </p> </li> <li> <p>aliskiren 150 mg: (RR 1.64, 95% CI 0.78 to 3.46; participants = 2277; studies = 7; I<sup>2</sup> = 0%); </p> </li> <li> <p>aliskiren 300 mg: (RR 1.84, 95% CI 0.89 to 3.81; participants = 2268; studies = 7; I<sup>2</sup> = 0%); and </p> </li> <li> <p>aliskiren 600 mg: (RR 7.00, 95% CI 2.48 to 19.72; participants = 592; studies = 2; I<sup>2</sup> = 0%). </p> </li> </ol> </p> </section> <section id="CD007066-sec-0098"> <h5 class="title">Angioedema:</h5> <p>No journal‐published study reported angioedema. The <a href="./references#CD007066-bbs2-0057" title="Center for drug evaluation and research. Tekturna (Aliskiren) Medical Review. FDA database March 5th 2007, issue Application number 21‐985:1‐283. ">FDA Medical Review 2007</a> reporting angioedema are the following. </p> <p> <ol id="CD007066-list-0023"> <li> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a> reports angioneurotic oedema occurred in valsartan 160 mg (n = 1, 1.7%). In the FDA medical review, this is described as "moderate facial edema diagnosed as angioedema. Drug was discontinued and the edema resolved. This patient had a similar episode with an ACE inhibitor." The FDA medical review also reports an event of facial oedema (n = 1) that appears to be angioedema, beginning with treatment and resolving eight days after discontinuing treatment. A third event of ankle and periorbital oedema (n = 1) is reported in the aliskiren 300 mg/valsartan 320 mg group beginning five days into treatment and resolving three days after discontinuing treatment. </p> </li> <li> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> reports 'peripheral oedema' (n = 1, aliskiren 300 mg) as a reason for study discontinuation. However, the FDA medical review (2007) reports a separate event in greater detail: "A 61 year‐old diabetic white male in the aliskiren 75mg group developed dyspnoea and edema of the lower limb to the knee, hands and face (eyelid but no lip or tongue) on day 22. He also had purplish‐blue lesions with angiomatous aspect on the upper part of his trunk. He completed the study with continuation of the edema and also developed anorexia, weight loss, tachycardia and elevated CRP." The regulator comments that "the participant was diagnosed with scleredema, and that the investigator confirmed that there was no evidence of heart failure at baseline and suspected angioedema." </p> </li> <li> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> ‐The FDA medical review describes that a patient in the aliskiren 300 mg group reported "Oedema hands and feet" on day 53. The regulator suggests this case may represent angioedema. </p> </li> </ol> </p> </section> </section> <section id="CD007066-sec-0099"> <h4 class="title">Subgroup analysis from FDA medical review</h4> <p>The <a href="./references#CD007066-bbs2-0057" title="Center for drug evaluation and research. Tekturna (Aliskiren) Medical Review. FDA database March 5th 2007, issue Application number 21‐985:1‐283. ">FDA Medical Review 2007</a> provided additional information regarding mean placebo‐corrected change from baseline in BP by dose and gender (<a href="#CD007066-tbl-0002">Table 1</a>); dose and age (<a href="#CD007066-tbl-0003">Table 2</a>); and dose and race (<a href="#CD007066-tbl-0004">Table 3</a>) from five placebo‐controlled studies (<a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>; <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>). </p> <p>The FDA medical reviewer comments: "In the multivariate regressions aliskiren shows a clear dose‐response from 75 through 600 mg for both SBP and DBP. Blacks show a reduced response and Asians an increased response with statistically significant interaction term with aliskiren use for Asians for DBP and almost statistically significant for Blacks for DBP. The interaction term for age &gt; 65 years and drug is statistically significant for SBP. There appear to be differences in response in various sub groups with aliskiren use. Blacks respond poorly to aliskiren monotherapy while Asians and the elderly may respond to lower doses." </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007066-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007066-sec-0100"></div> <p>To our knowledge this is the first systematic review to use clinical study reports (CSRs) and other regulatory documents to report on a more comprehensive set of efficacy and safety data regarding dose‐related blood pressure lowering efficacy of renin inhibitors versus placebo. As a result, this updated review provides more detailed information regarding mortality, non‐fatal serious adverse events, total adverse events and specific adverse events. Though we found outcome reporting to be far more extensive within CSRs as compared to journal‐published studies, even access to these regulatory documents remain insufficient as a means to correct for reporting bias. Our attention was drawn to the discrepant reporting or non‐reporting of important safety outcomes, discovered by closely reading the FDA medical review of Dr. Thomas Marciniak. These findings have increased our awareness for the need to access the patient narratives on adverse events located within the appendices of CSRs. Further to this, individual patient data and access to all case reports and narratives are likely needed to report more completely on the harms and efficacy of aliskiren. Given the EMA can provide de‐identified patient narratives on serious and non‐serious adverse events, we question the reasons the sponsor, Novartis, has for not providing any case narratives to researchers who are granted data‐sharing privileges through the CSDR platform. Though obtaining the data from CSR bodies has increased our ability to report more extensively on efficacy and safety outcomes, we remain unable to accurately depict the clinical safety, usefulness and value of aliskiren. As to whether aliskiren results in greater benefit than harm to patients remains unclear. This is a direct result of not having access to the entire complement of evidence. </p> <p>We have not identified any randomized controlled trials (RCTs) evaluating the effectiveness of renin inhibitors as compared to placebo in reducing mortality and morbidity, as well as documenting the long‐term reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP), which is the goal of antihypertensive therapy. </p> <p><a href="./references#CD007066-bbs2-0099" title="ZhangJing‐Tao , ChenKe‐Ping , GuanTing , ZhangShu . Effect of aliskiren on cardiovascular outcomes in patients with pre ‐hypertension: a meta‐analysis of randomized controlled trials. Drug Design, Development and Therapy2015;9:1963‐71. ">Zhang 2015</a> conducted a systematic review of RCTS comparing the effect of aliskiren versus non‐aliskiren therapy on major cardiovascular outcomes in clinically diverse patients with hypertension. Based on six studies (<a href="./references#CD007066-bbs2-0044" title="ParvingHH , BrennerBM , McMurrayJH , ZeeuwD , HaffnerSM , Solomon , et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New England Journal of Medicine2012;367:2204‐13. ">ALTITUDE 2012</a>; <a href="./references#CD007066-bbs2-0049" title="PerssonF , LewisJB , LewisEJ , RossingP , HollenbergNK , ParvingHH . Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Clin J Am Soc NephrolMay 2011;6(5):1025‐31. [DOI: 10.2215/CJN.07590810] ">AVOID 2011</a>; <a href="./references#CD007066-bbs2-0048" title="SciricaBM , MorrowDA , BodeC , RuzylloW , RudaM , Oude OphuisAJ , Lopez‐SendonJ , SwedbergK , OgorekM , RifaiN , LukashevichV , MaboudianM , CannonCP , McCabeCH , BraunwaldE . Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE‐TIMI 43 Trial. European Heart Journal2010;31(16):1993‐2005. ">AVANT GARDE ‐ TIMI 43 2010</a>; <a href="./references#CD007066-bbs2-0046" title="SolomonSD , ShinSH , ShahA , SkaliH , DesaiA , KoberL , MaggioniAP , RouleauJL , KellyRY , HesterA , McMurrayJJ , PfefferMA . Aliskiren Study in Post‐MI Patients to Reduce Remodeling (ASPIRE) Investigators. European Heart JournalMay 2011;32:1227‐34. ">ASPIRE 2011</a> ; <a href="./references#CD007066-bbs2-0047" title="GheorghiadeM , BöhmM , GreeneSJ , FonarowGC , LewisEF , ZannadF , SolomonSD , BaschieraF , BothaJ , HuaTA , GimpelewiczCR , JaumontX , LesogorA , MaggioniAP , ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA March 20 2013;309(11):1125‐35. ">ASTRONAUT 2013</a>; and <a href="./references#CD007066-bbs2-0045" title="NichollsSJ , BakrisGL , KasteleinJP , et al. Effect of Aliskiren on Progression of Coronary Disease in Patients With PrehypertensionThe AQUARIUS Randomized Clinical Trial. JAMA2013;310(11):1135‐44. ">AQUARIUS 2013</a>), reporting data in 12,465 patients, the authors concluded that aliskiren had no effect (RR with 95% CI) on major cardiovascular events 0.93 (0.77 to 1.13), total mortality 1.00 (0.77 to 1.29), cardiac death 1.01 (0.79 to 1.29), myocardial infarction 0.71 (0.36 to 1.38), or stroke 0.87 (0.48 to 1.58). </p> <section id="CD007066-sec-0101"> <h3 class="title" id="CD007066-sec-0101">Summary of main results</h3> <p>Aliskiren at all doses lowered both SBP and DBP as compared to placebo ranging from ‐3.0 to ‐11.4 mmHg for SBP and ‐2.1 to ‐5.9 mmHg for DBP. There was a significant dose response for the 75 mg, 150 mg and 300 mg doses. The effect of 600 mg of aliskiren was not different from 300 mg. Information in this update from nine available CSRs obtained from EMEA did not result in altering the magnitude of reduction in mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) at any dose as compared to placebo from the previous 2011 update as the 95% confidence intervals (CIs) overlapped. </p> <p>Comparison between various doses within the same study showed that aliskiren 150 mg lowered SBP/DBP more than aliskiren 75 mg (‐1.9/‐0.8 mmHg); aliskiren 300 mg lowered SBP/DBP more than aliskiren 150 mg (‐2.6/‐1.8 mmHg); and aliskiren 600 mg lowered SBP/DBP more than aliskiren 150 mg ‐3.4/‐2.2 mmHg, However, SBP/DBP lowering did not differ between aliskiren 600 mg versus aliskiren 300 mg. </p> <p>The magnitude of the BP lowering with aliskiren at the maximum recommended dose of 300 mg daily ‐7.9/‐4.5 mm Hg is similar to what has been determined using similar methods in systematic reviews of angiotensin‐converting‐enzyme inhibitors (ACEIs), ‐8/‐5 mm Hg and angiotensin receptor blockers (ARBs) ‐8/‐5 mm Hg (<a href="./references#CD007066-bbs2-0065" title="HeranBS , WongMMY , HeranIK , WrightJM . Dose‐related blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors in the treatment of primary hypertension. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD003823] ">Heran 2008a</a>; <a href="./references#CD007066-bbs2-0066" title="HeranBS , WongMMY , HeranIK , WrightJM . Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD003822.pub2] ">Heran 2008b</a>; <a href="./references#CD007066-bbs2-0075" title="LawMR , WaldNJ , MorrisJK , JordanRE . Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ2003;326(7404):1427. [PUBMED: 12829555] ">Law 2003)</a>. Direct comparison of renin inhibitor with ARBs from the three placebo‐controlled studies included in this systematic review that compared aliskiren 300 mg with ARBs also support this finding. </p> <p> <ol id="CD007066-list-0024"> <li> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a> study: aliskiren 300 mg lowered MSSBP as well as MSDBP as compared to baseline to a similar extent as valsartan 320 mg at week eight (SBP : ‐13.0 mm Hg versus ‐12.8 mm Hg, respectively and DBP: ‐9.0 mm Hg versus ‐9.7 mm Hg, respectively). </p> </li> <li> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a> study: aliskiren 300 mg lowered MSSBP as well as MSDBP as compared to baseline to a similar extent as valsartan 320 mg at week eight (SBP: ‐5.08 mm Hg versus ‐6.54 mm Hg and DBP: ‐ 3.67mm Hg versus ‐2.69 mm Hg). </p> </li> <li> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> study: aliskiren 150 mg lowered MSSBP as well as MSDBP as compared to baseline to a similar extent as irbesartan 150 mg at week eight (SBP: ‐6.01 mm Hg versus ‐7.21 mm Hg and DBP: ‐2.94 mm Hg versus ‐2.54 mm Hg). </p> </li> </ol> </p> <p>This suggests that inhibiting the renin angiotensin system at different sites does not lead to any clinically different BP lowering effects. Adequately powered RCTs assessing different classes of drugs in head‐to‐head studies are the best way to look for clinically significant differences in BP lowering effect. </p> <p>The AHRQ review 2011 update by <a href="./references#CD007066-bbs2-0086" title="PowersB , GreeneL , BalfeLM . Updates on the treatment of essential hypertension: a summary of AHRQ's comparativeeffectiveness review of angiotensin‐converting enzyme inhibitors, angiotensin II receptorblockers, and direct renin inhibitors. Journal of Managed Care PharmacyOctober 2011;17(8):Supplement S1‐S14. ">Powers 2011</a> concluded that studies evaluating the renin inhibitors aliskiren versus ACEIs and ARBs on mortality and morbidity outcomes were relatively short, and few deaths or cardiovascular events occurred, resulting in insufficient evidence to discern differences. They also reported that a random‐effects meta‐analysis of 23 RCTs comparing ACEIs and ARBs found no significant difference in the proportion of patients who achieved successful BP control on a single antihypertensive agent. </p> <p>This update provides additional details on adverse events from CSRs. During the double‐blind period, there were two (0.04%) deaths and 27 (0.5%) non‐fatal serious adverse events in 5120 patients in the aliskiren monotherapy arm as compared to one (0.04%) death and 14 (0.6%) non‐fatal serious adverse events in 2319 patients in the placebo group. There were no differences in all‐cause mortality and non‐fatal serious adverse events. The durations (eight to 13 weeks) of the included studies were too short and were not adequately powered to detect differences in adverse events between aliskiren and placebo. Journal‐published studies and clinical study summaries listed only a few events, generally those with an incidence greater than 1% to 2.5% in any group, while others reported by broad systems affected by the drugs: cardiac, immune system, respiratory, etc. The most common adverse events reported were headache, nasopharyngitis, dizziness, and back pain, which were similar in placebo groups and aliskiren groups at all doses. Consistent with the FDA medical review, we have determined a statistically significant, dose‐dependent relationship between aliskiren 600 mg and diarrhoea. Due to the limited duration of the studies, it is impossible to determine whether diarrhoea is merely a marker for more serious adverse outcomes that may require longer periods of time to develop. This review found low‐quality evidence that with short‐term use, aliskiren does not increase withdrawal due to adverse effects as compared to placebo. </p> </section> <section id="CD007066-sec-0102"> <h3 class="title" id="CD007066-sec-0102">Overall completeness and applicability of evidence</h3> <p>There are numerous ways we have experienced a lack of access to the entire complement of evidence and encountered limitations accordingly. Although this update is based primarily on CSRs, which are far more comprehensive than journal‐published trials, we were only able to obtain nine CSRs of the 12 studies that met the inclusion criteria of this review, provided the EMA does not possess the other three studies. In addition, of the nine CSRs we have obtained, we do not yet possess the appendices, which contain valuable and revealing information (e.g. patient narratives), as has been previously discussed. Overt publication bias can be noted as two studies do not have a corresponding journal publications (<a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> and <a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a>), but can also be demonstrated by a lack of public trial registration. Five of 12 studies (42%) are not registered on ClinicalTrials.gov (<a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; <a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>; <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>). Of the seven studies that are registered, three trials (43%) do not have any study results posted on the ClinicalTrials.gov web site. These findings cause us to question the degree to which the 2007 US Food and Drug Administration Amendments Act is followed, as it mandates that all drugs and devices approved for use must be publicly registered at ClinicalTrials.gov within 24 months of trial completion, regardless of whether the trial is published. Of the studies included within this review, we have observed trials that are not journal‐published, not registered publicly, and are not possessed by the European regulatory authority. A combination of all three situations would effectively hide the existence of a trial, which could distort the evidence, mislead health policy and prescribing practices. Although we have tried to diligently include all available information from multiple sources, we have encountered various obstacles that limit our ability to evaluate the safety and efficacy of aliskiren as compared to placebo. </p> <section id="CD007066-sec-0103"> <h4 class="title">Safety Warning</h4> <p>Although aliskiren has shown a good safety and tolerability profile in short‐term studies in adult patients with hypertension, the Food and Drug Administration (FDA) has recently issued a warning about combining aliskiren with ACEIs and ARBs in patients diagnosed with diabetes or renal impairment. </p> <p>A recent RCT (<a href="./references#CD007066-bbs2-0044" title="ParvingHH , BrennerBM , McMurrayJH , ZeeuwD , HaffnerSM , Solomon , et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New England Journal of Medicine2012;367:2204‐13. ">ALTITUDE 2012</a>) was halted prematurely due to safety concerns when aliskiren 300 mg daily was used as an adjunctive therapy with an ACEI or an ARB. This study enrolled adults 35 years of age or older with type 2 diabetes and evidence of microalbuminuria, macroalbuminuria, or cardiovascular disease. </p> <p> <ol id="CD007066-list-0025"> <li> <p>A second interim efficacy analyses of the data from 8561 participants found that adjunct therapy of aliskiren with ARBs or ACEIs (n = 4274) contributed to an increased rate of adverse events and did not reduce cardiovascular or renal outcomes as compared to placebo (n = 4287) after a median follow up of 32.9 months. </p> <ul class="plain" id="CD007066-list-0026"> <li> <ol id="CD007066-list-0027"> <li> <p>The primary endpoint was cardiovascular death or a first occurrence of cardiac arrest with resuscitation, myocardial infarction, stroke, unplanned hospitalization for heart failure, end stage renal disease, death attributable to kidney failure, or loss of kidney function, and doubling of baseline serum creatinine. It occurred in 783 (18.3%) of patients assigned to aliskiren as compared with 732 (17.1%) in the placebo arm (hazard ratio (HR), 1.08, 95% CI, 0.98 to 1.20; P = 0.12). </p> </li> <li> <p>Within the primary endpoint, 19 participants experienced cardiac arrest requiring resuscitation versus eight patients assigned to placebo (HR, 2.40, 95% CI 1.05 to 5.48; P = 0.04). </p> </li> </ol> </li> </ul> </li> <li> <p>The proportion of patients with hyperkalaemia (serum potassium level, ≥6 mmol/L) was significantly higher in the aliskiren group than in the placebo group (11.2% versus 7.2%), as was the proportion with reported hypotension (12.1% versus 8.3%) and diarrhoea (9.8% versus 7.3%) (P &lt; 0.001 for all comparisons). </p> </li> <li> <p>During the study, 1445 patients assigned to aliskiren (33.8%) and 1218 assigned to placebo (28.4%) discontinued the study drug permanently for a reason other than death (P = 0.001). </p> </li> <li> <p>In the aliskiren group, 563 patients (13.2%) discontinued the study drug because of an adverse event, as compared with 437 patients (10.2%) in the placebo group (P &lt; 0.001). </p> </li> <li> <p>Favourable results for the aliskiren group were seen with respect to surrogate markers such as lower SBP and DBP measurements (1.3 and 0.6 mm Hg, respectively), and reduced urinary albumin excretion as compared to placebo. </p> </li> </ol> </p> <p>However, the authors concluded that "A number of studies of various drugs have shown favourable changes in surrogate markers of disease progression, with subsequent studies of morbidity and mortality documenting a lack of clinical benefit or even harm. The present study documented more adverse events in the aliskiren group than in the placebo group without clinical benefits to offset them, which underscores the need to go beyond surrogate bio‐markers and obtain risk‐benefit data from clinical endpoint studies to better inform clinical decisions" (<a href="./references#CD007066-bbs2-0044" title="ParvingHH , BrennerBM , McMurrayJH , ZeeuwD , HaffnerSM , Solomon , et al. ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New England Journal of Medicine2012;367:2204‐13. ">ALTITUDE 2012</a>). </p> <p><a href="./references#CD007066-bbs2-0062" title="HarelZ , GilbertC , WaldR , BellC , PerlJ , JuurlinkD , et al. The effect of combination treatment with aliskiren and blockers of the renin‐angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta‐analysis. BMJ2012;344(e42):1‐13. [DOI: 10.1136/bmj.e42] ">Harel 2012</a> conducted a systematic review comparing combined treatment using aliskiren and ACEIs or ARBs with monotherapy in 4814 participants from 10 RCTS. Harel also concluded that use of aliskiren in combination with ACEIs or ARBs is associated with an: </p> <p> <ol id="CD007066-list-0028"> <li> <p>increased risk for hyperkalaemia as compared to ACEI or ARB monotherapy RR with 95% CI 1.58 (1.24 to 2.02) as well as aliskiren monotherapy RR with 95% CI 1.67 (1.01 to 2.79). </p> </li> <li> <p>The risk of acute kidney injury did not differ significantly between the combined therapy and monotherapy groups (RR 1.14, 0.68 to 1.89). </p> </li> </ol> </p> <p><a href="./references#CD007066-bbs2-0077" title="MakaniH , BangaloreS , DesouzaK , ShahA , MesserliF . Efficacy and safety of dual blockade of the renin‐angiotensin system: meta‐analysis of randomised trials. BMJ2013;346(f360):1‐15. [DOI: 10.1136/bmj.f360] ">Makani 2013</a> conducted a similar systematic review of combined treatment using aliskiren and ACEIs or ARBs with monotherapy with these agents in 68,405 participants from 33 RCTs. Makani concluded that although dual blockade of the renin‐angiotensin system may have seemingly beneficial effects on certain surrogate endpoints, it failed to reduce mortality and was associated with an excessive risk of adverse events such as hyperkalaemia, hypotension, and renal failure compared with monotherapy. The authors concluded that the risk to benefit ratio argues against the use of dual therapy. </p> </section> <section id="CD007066-sec-0104"> <h4 class="title">Regulatory Marketing Authorization</h4> <p>Rasilez (aliskiren) remains approved with the EMA, but Tekturna (aliskiren) has been withdrawn. Enviage (aliskiren) and Sprimeo (aliskiren) have also been withdrawn with the EMA. But Tekturna (aliskiren) remains approved for marketing with the FDA. Additionally, for both the FDA and EMA, a number of combination treatments have had their marketing authorization withdrawn, through a combination of voluntary withdrawal and forced withdrawal from the regulatory body. <a href="./references#CD007066-bbs2-0092" title="FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna). http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm#data Last updated on19th January 2016. ">U.S. Food and Drug Administration 2016</a>. </p> </section> </section> <section id="CD007066-sec-0105"> <h3 class="title" id="CD007066-sec-0105">Quality of the evidence</h3> <p>We used the GRADE approach to build a 'Summary of Findings' table as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007066-bbs2-0090" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJj , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). Available from www.cochrane‐handbook.org: The Cochrane Collaboration, 2011. ">Schünemann 2011</a>). We used the GRADE approach to rate the quality of the evidence as 'high', 'moderate' 'low', or 'very low' using the five GRADE considerations. </p> <p> <ol id="CD007066-list-0029"> <li> <p>Risk of bias: not serious; serious; or very serious.</p> </li> <li> <p>Inconsistency: not serious; serious; or very serious.</p> </li> <li> <p>Indirectness: not serious; serious; or very serious.</p> </li> <li> <p>Imprecision: not serious; serious; or very serious.</p> </li> <li> <p>Publication bias: undetected; or strongly suspected.</p> </li> </ol> </p> <p>We reported 'Summary of Findings' tables for SBP, DBP and diarrhoea. Although the inclusion criteria of the 12 studies was high quality to begin with ‐ randomized double‐blind studies, the overall quality of evidence is graded as moderate‐quality evidence for BP outcome and low‐quality evidence for adverse event outcomes because of a number of limitations in this systematic review. Refer to the 'Risk of bias' assessment of individual studies <a href="#CD007066-fig-0002">Figure 2</a> as well as reasons for downgrading evidence in the <a href="./full#CD007066-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD007066-sec-0106"> <h3 class="title" id="CD007066-sec-0106">Potential biases in the review process</h3> <p>Publication bias is evident as it has come to our attention that several studies were not registered on ClinicalTrials.gov (<a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a>; <a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a>; <a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>; <a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>). The EMA does not possess CSRs of <a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a>, <a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a>, or <a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a>. </p> <p><a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> and <a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> do not have corresponding journal‐published studies. </p> <p>With respect to the dose‐ranging BP lowering effect size as reported above and shown in forest plots, this could be an overestimate of the magnitude of BP lowering due to publication bias and also because wide confidence intervals in effect size for some doses were observed. All included studies were sponsored by the manufacturer, Novartis. Requests for the unpublished studies have not been granted. It is possible that negative studies exist, which have not been published and therefore are not included in this meta‐analysis. In addition, the BP lowering efficacy estimate is over a short duration (eight to 13 weeks). </p> <p>No study is available as yet evaluating effectiveness of long‐term renin inhibitor monotherapy on clinically relevant outcomes such as (mortality, cardiovascular and cerebrovascular morbidity). </p> </section> <section id="CD007066-sec-0107"> <h3 class="title" id="CD007066-sec-0107">Agreements and disagreements with other studies or reviews</h3> <section id="CD007066-sec-0108"> <h4 class="title">Comparison with other systematic reviews</h4> <p>Several systematic reviews published by <a href="./references#CD007066-bbs2-0095" title="WeirMR , BushC , AndersonDR , ZhangJ , KeefeD , SatlinA . Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Journal of the American Society of Hypertension2007;1(4):264‐77. ">Weir 2007</a>; <a href="./references#CD007066-bbs2-0096" title="WhiteWB , BresalierR , KaplanAP , PalmerBF , RiddellRH , LesogorA , et al. Safety and tolerability of the direct renin Inhibitor Aliskiren: A pooled analysis of clinical experience in more than 12,000 patients with hypertension. Journal of Clinical Hypertension2010;12(10):765‐75. ">White 2010</a>; <a href="./references#CD007066-bbs2-0061" title="GradmanAH , WeirMR , WrightM , BushCA , KeefeDL . Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies. Journal of Human Hypertension2010;24:721‐9. ">Gradman 2010</a>; and <a href="./references#CD007066-bbs2-0051" title="ChenY , MengL , ShaoH , FengYu . Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta‐analysis. Hypertension Research2013;36:252‐61. ">Chen 2013</a> were limited to a smaller subset of included studies and provide very limited information regarding adverse events. </p> <p><a href="./references#CD007066-bbs2-0095" title="WeirMR , BushC , AndersonDR , ZhangJ , KeefeD , SatlinA . Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Journal of the American Society of Hypertension2007;1(4):264‐77. ">Weir 2007</a> published pooled analysis of antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren alone, and in combination with other antihypertensive agents, from seven randomized, multicentre studies in patients with hypertension. Data were available for 7045 patients (mean age 52.5 to 59.8 years, 50.2% to 72.5% men) with mild‐to‐moderate hypertension (mean sitting diastolic blood pressure (MSDBP) 95 mm Hg to 109 mm Hg) over treatment durations of six to eight weeks. </p> <p> <ol id="CD007066-list-0030"> <li> <p>In placebo‐controlled studies, aliskiren reduced MSDBP from baseline by 8.6 to 12.1/7.2 to 10.3 mm Hg (75 mg), 8.7 to 13.0/7.8 to 10.3 mm Hg (150 mg), 14.1 to 15.8/10.3 to 12.3 mm Hg (300 mg), and 15.7 to 15.8/11.5 to 12.5 mm Hg (600 mg), compared with 2.9 to 10.0/3.3 to 8.6 mm Hg for placebo. </p> </li> <li> <p>Aliskiren demonstrated comparable efficacy in patients aged &gt; 65 years old or &lt; 65 years old, in men and women, and it lowered BP effectively in all racial subgroups. </p> </li> <li> <p>Rates of discontinuation due to adverse events were low (1.7% to 2.6%).</p> </li> <li> <p>The most frequently reported adverse events with aliskiren were headache (5.7%), nasopharyngitis (4.4%), diarrhoea (2.6%), dizziness (1.8%) and fatigue (1.6%). </p> </li> <li> <p>The overall incidence of adverse events with aliskiren monotherapy was similar to placebo (39.8% versus 40.2%, respectively). </p> </li> <li> <p>The incidence of diarrhoea with aliskiren was higher than placebo due to a significantly higher rate with aliskiren 600 mg (P = .0001 versus placebo). </p> </li> </ol> </p> <p><a href="./references#CD007066-bbs2-0096" title="WhiteWB , BresalierR , KaplanAP , PalmerBF , RiddellRH , LesogorA , et al. Safety and tolerability of the direct renin Inhibitor Aliskiren: A pooled analysis of clinical experience in more than 12,000 patients with hypertension. Journal of Clinical Hypertension2010;12(10):765‐75. ">White 2010</a> published pooled analysis of safety and tolerability of aliskiren in more than 12,000 patients with hypertension. Twelve randomized double‐blind clinical studies in patients with hypertension were evaluated: eight short‐term (8‐week) placebo‐controlled studies and four long‐term (26‐ to 52‐week) active‐controlled studies. </p> <p>In short‐term studies:</p> <p> <ol id="CD007066-list-0031"> <li> <p>adverse events occurred in similar proportions of aliskiren 150 mg and 300 mg (33.6% and 31.6%, respectively) and placebo treatment groups (36.8%); </p> </li> <li> <p>in placebo‐controlled studies, the incidence of angioedema ⁄ urticaria was lower in patients receiving aliskiren 150 mg (0.2%) and aliskiren 300 mg (0.3%) than in the placebo group (0.5%; RR, 0.31; 95% CI, 0.07 to 1.47 for 150 mg; RR, 0.57; 95% CI, 0.17 to 1.89 for 300 mg); </p> </li> <li> <p>cough was not significantly different for aliskiren (0.7% to 1.4%) versus placebo (0.7%); </p> </li> <li> <p>hyperkalaemia was 0.1% in aliskiren 300 mg group and 0.1% in the placebo group.</p> </li> </ol> </p> <p>Analysis by individual aliskiren monotherapy dose demonstrated no significant increase in diarrhoea compared with placebo for patients receiving aliskiren 150 mg (RR, 1.18; 95% CI, 0.62 to 2.24) or 300 mg (RR, 1.62; 95% CI, 0.91 to 2.90). No patient receiving short‐term treatment with aliskiren 150 mg or 300 mg discontinued due to diarrhoea. There was no evidence for an increased risk of gastrointestinal bleeding or ulceration with aliskiren treatment over placebo in the short‐term studies (RR, 0.62; 95% CI, 0.06 to 6.87 for aliskiren 150 mg and RR, 0.57; 95% CI, 0.05 to 6.28 for aliskiren 300 mg). </p> <p><a href="./references#CD007066-bbs2-0061" title="GradmanAH , WeirMR , WrightM , BushCA , KeefeDL . Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies. Journal of Human Hypertension2010;24:721‐9. ">Gradman 2010</a> published a pooled analysis of efficacy, safety and tolerability of monotherapy with the direct renin inhibitor aliskiren (150 mg and 300 mg) over eight to 12 weeks in women with mild‐to‐moderate hypertension with MSDBP &gt; 95 and &lt; 110 mmHg across eight randomized and double‐blind studies. Safety and tolerability were assessed in the five placebo‐controlled studies in the analysis. </p> <p> <ol id="CD007066-list-0032"> <li> <p>Women participating in the studies tended to be slightly older than men (range of means 55.1–57.3 years versus 52.9 to 55.3 years), with a longer duration of hypertension (7.8 to 8.2 years versus 6.5 to 7.8 years). </p> </li> <li> <p>There was a higher proportion of Black women (5.0% to 17.7%) than Black men (2.2% to 8.5%); conversely the proportion of Asian women (7.7% to 10.4%) was lower than the proportion of Asian men (12.8% to 25.5%). </p> </li> <li> <p>Slightly more women than men were obese (40.8% to 42.8% versus 31.1% to 37.7%).</p> </li> <li> <p>Baseline BP was similar in women and men.</p> </li> </ol> </p> <p>In the 1527 women enrolled in these studies:</p> <p> <ol id="CD007066-list-0033"> <li> <p>aliskiren 150 mg and 300 mg produced significantly greater BP reductions (14.1/11.0 and 16.1/12.3 mmHg, respectively) compared with placebo (7.2/7.6 mmHg; P &lt; 0.0001); </p> </li> <li> <p>BP reductions with aliskiren monotherapy in women were similar to those observed in men, and consistent across subgroups of age, metabolic syndrome and obesity; </p> </li> <li> <p>the overall incidence of adverse events in women was similar with aliskiren treatment (150 mg, 42.3%; 300 mg, 46.0%); and placebo (39.0%); </p> </li> <li> <p>adverse events with aliskiren were more frequent in women than in men, consistent with previous studies of gender differences in drug tolerability; </p> </li> <li> <p>few patients in this analysis discontinued aliskiren treatment and the incidence was similar in women (150 mg, 7.3%; 300 mg, 5.8%); and men (150 mg, 6.8%; 300 mg, 6.6%); </p> </li> <li> <p>discontinuation rates with placebo were higher than with aliskiren therapy for both women (12.5%) and men (12.9%), primarily because of the higher numbers of discontinuations due to unsatisfactory therapeutic effect with placebo (5.0% to 5.6%) than with active therapy (1.5% to 2.3%). The reasons for discontinuation from aliskiren treatment were similar across doses and genders, with adverse events (0.8% to 2.7%) and withdrawal of consent (0.9% to 2.3%) being the most commonly reported reasons. </p> </li> </ol> </p> <p><a href="./references#CD007066-bbs2-0051" title="ChenY , MengL , ShaoH , FengYu . Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta‐analysis. Hypertension Research2013;36:252‐61. ">Chen 2013</a> investigated the antihypertensive effects and tolerability of aliskiren in comparison with other antihypertensive drugs and placebo in patients with hypertension. Nine studies included study arms with placebo, involving 3541 patients. They did not provide dose‐ranging decrease in SBP and DBP. Results were only shown for aliskiren at 300 mg dose and it was significantly superior to placebo in lowering both DBP and SBP WMD ‐4.75, 95% CI ‐5.59 to ‐3.92, P &lt; 0.00001; MD ‐8.12, 95% CI ‐9.61 to ‐6.63, P &lt; 0.00001, respectively). The Chen 2013 meta‐analysis indicates that aliskiren is associated with a similar incidence of adverse events and discontinuation due to adverse events to placebo. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007066-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA Study flow diagram." data-id="CD007066-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgments about each methodological quality item for each included study." data-id="CD007066-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgments about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Aliskiren vs. placebo, outcome: 1.1 Systolic BP.Highly significant subgroup differences were observed therefore mean overall effect size across all doses is not shown. The number of placebo group patients are divided equally in dose ranging studies when more than one dose of aliskiren was used.CSPP100A2308 study the SBP reduction in the treatment and placebo group are reported from the CSR page 61.CSPP100A2405 study the SD for all treatment groups are calculated from SEM reported on page 7 in the CSR ." data-id="CD007066-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Aliskiren vs. placebo, outcome: 1.1 Systolic BP.</p> <p>Highly significant subgroup differences were observed therefore mean overall effect size across all doses is not shown. The number of placebo group patients are divided equally in dose ranging studies when more than one dose of aliskiren was used. </p> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> study the SBP reduction in the treatment and placebo group are reported from the CSR page 61. </p> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a> study the SD for all treatment groups are calculated from SEM reported on page 7 in the CSR . </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Aliskiren vs. placebo, outcome: 1.2 Diastolic BP.Highly significant subgroup differences were observed, therefore mean overall effect size across all doses is not shown. The number of placebo group patients are divided equally in dose ranging studys when more than one dose of aliskiren was used.CSPP100A2308 study the DBP reduction in the treatment and placebo group are reported from the CSR which differ from those reported in the published article. The previous version of this review used data from the published article.CSPP100A2405 study the SD for all treatment groups are calculated from SEM reported from the CSR on page 8." data-id="CD007066-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Aliskiren vs. placebo, outcome: 1.2 Diastolic BP.</p> <p>Highly significant subgroup differences were observed, therefore mean overall effect size across all doses is not shown. The number of placebo group patients are divided equally in dose ranging studys when more than one dose of aliskiren was used. </p> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> study the DBP reduction in the treatment and placebo group are reported from the CSR which differ from those reported in the published article. The previous version of this review used data from the published article. </p> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a> study the SD for all treatment groups are calculated from SEM reported from the CSR on page 8. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aliskiren vs. placebo, Outcome 1 Systolic BP." data-id="CD007066-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Aliskiren vs. placebo, Outcome 1 Systolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aliskiren vs. placebo, Outcome 2 Diastolic BP." data-id="CD007066-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Aliskiren vs. placebo, Outcome 2 Diastolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aliskiren vs. placebo, Outcome 3 Withdrawals due to adverse event." data-id="CD007066-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Aliskiren vs. placebo, Outcome 3 Withdrawals due to adverse event.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aliskiren vs. placebo, Outcome 4 Cough." data-id="CD007066-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Aliskiren vs. placebo, Outcome 4 Cough.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aliskiren vs. placebo, Outcome 5 Diarrhoea." data-id="CD007066-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Aliskiren vs. placebo, Outcome 5 Diarrhoea.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aliskiren150 mg vs. Aliskiren 75 mg, Outcome 1 Systolic BP." data-id="CD007066-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Aliskiren150 mg vs. Aliskiren 75 mg, Outcome 1 Systolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Aliskiren150 mg vs. Aliskiren 75 mg, Outcome 2 Diastolic BP." data-id="CD007066-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Aliskiren150 mg vs. Aliskiren 75 mg, Outcome 2 Diastolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Aliskiren 300 mg Vs. Aliskiren 75 mg, Outcome 1 SBP." data-id="CD007066-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Aliskiren 300 mg Vs. Aliskiren 75 mg, Outcome 1 SBP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Aliskiren 300 mg Vs. Aliskiren 75 mg, Outcome 2 DBP." data-id="CD007066-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Aliskiren 300 mg Vs. Aliskiren 75 mg, Outcome 2 DBP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Aliskiren 300 mg vs. Aliskiren 150 mg, Outcome 1 Systolic BP." data-id="CD007066-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Aliskiren 300 mg vs. Aliskiren 150 mg, Outcome 1 Systolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Aliskiren 300 mg vs. Aliskiren 150 mg, Outcome 2 Diastolic BP." data-id="CD007066-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Aliskiren 300 mg vs. Aliskiren 150 mg, Outcome 2 Diastolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Aliskiren 600 mg vs. Aliskiren 150 mg, Outcome 1 SBP." data-id="CD007066-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Aliskiren 600 mg vs. Aliskiren 150 mg, Outcome 1 SBP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Aliskiren 600 mg vs. Aliskiren 150 mg, Outcome 2 DBP." data-id="CD007066-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Aliskiren 600 mg vs. Aliskiren 150 mg, Outcome 2 DBP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Aliskiren 600 mg vs. Aliskiren 300 mg, Outcome 1 Systolic BP." data-id="CD007066-fig-0018" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Aliskiren 600 mg vs. Aliskiren 300 mg, Outcome 1 Systolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007066-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/urn:x-wiley:14651858:media:CD007066:CD007066-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_t/tCD007066-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Aliskiren 600 mg vs. Aliskiren 300 mg, Outcome 2 Diastolic BP." data-id="CD007066-fig-0019" src="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Aliskiren 600 mg vs. Aliskiren 300 mg, Outcome 2 Diastolic BP.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/media/CDSR/CD007066/image_n/nCD007066-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007066-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Aliskiren compared to placebo for primary hypertension</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: primary hypertension </p> <p><b>Setting</b>: Outpatient </p> <p><b>Intervention</b>: Aliskiren </p> <p><b>Comparison</b>: Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b> Anticipated absolute effects<sup>*</sup> (95% CI)mmHg</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Effect with placebo<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Effect with Aliskiren<sup>2</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP ‐ Aliskiren 75 mg vs. placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.9 lower to 10.0 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.97 lower (4.76 lower to 1.18 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1100<br/> (5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP ‐ Aliskiren 150 mg vs. placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.0 lower to 10.0 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5.95 lower (6.85 lower to 5.06 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3786<br/> (12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE 4 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP ‐ Aliskiren 300 mg vs. placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.9 lower to 10.0 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>7.88 lower (8.94 lower to 6.82 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3009<br/> (10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE 5 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systolic BP ‐ Aliskiren 600 mg vs. placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3.8 lower to 5.3 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>11.35 lower (14.43 lower to 8.27 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>393<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊝⊝</b> <br/> LOW <sup>6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diastolic BP ‐ Aliskiren 75 mg vs placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3.2 lower to 8.6 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2.05 lower (3.13 lower to 0.96 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1100<br/> (5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diastolic BP ‐ Aliskiren 150 mg vs placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3.0 lower to 8.6 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3.16 lower (3.74 lower to 2.58 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3783<br/> (12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE <sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diastolic BP ‐ Aliskiren 300 mg vs placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3.2 lower to 8.6 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4.49 lower (5.17 lower to 3.82 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3001<br/> (10 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊕⊝</b> <br/> MODERATE <sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diastolic BP ‐ Aliskiren 600 mg vs placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>6.2 lower to 6.3 lower</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>5.86 lower (7.73 lower to 3.99 lower)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>393<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊝⊝</b> <br/> LOW <sup>6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Diarrhoea ‐</b> </p> <p>Aliskiren 600 mg vs placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>14 per 1,000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>95 per 1,000</b> <br/> (34 to 266) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 7.00<br/> (2.48 to 19.72)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>592<br/> (2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>⊕⊕⊝⊝</b> <br/> LOW <sup>6,7</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; <b>MD:</b> Mean Difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>1. Range of mean decrease in SBP and DBP mmHg as compared to baseline in the individual trials in the placebo group. </p> <p>2. Effects in Aliskiren group represent the blood pressure lowering effect in excess of that with placebo. </p> <p>3. Downgraded by 1 level for serious risk of bias (due to high likelihood of attrition, selective reporting and funding bias in all 5 included studies). Also study <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> had high likelihood of selection bias. </p> <p>4. Downgraded by one level for serious risk of bias (due to high likelihood of attrition, selective reporting and funding bias in all 12 included studies). </p> <p>5. Downgraded by one level for serious risk of bias (due to high likelihood of attrition, selective reporting and funding bias in all 10 included studies). </p> <p>6. Downgraded by 1 level for serious risk of bias (due to high likelihood of attrition, selective reporting and funding bias in both included studies). </p> <p>7. Downgraded by 1 more level due to wide confidence interval.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007066-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reported as table 21 in the FDA medical review (page 51): Reviewers mean placebo‐corrected change from baseline in BP by dose and gender based on 5 placebo controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Female</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Male</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>150 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>300 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>600 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reported as table 21 in the FDA medical review (page 51): Reviewers mean placebo‐corrected change from baseline in BP by dose and gender based on 5 placebo controlled studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007066-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Reported as table 22 in the FDA medical review (page 51): Reviewers mean placebo‐corrected change from baseline in BP by dose and age based on 5 placebo controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Age &lt; 65 years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Age &gt; 65 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>150 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>300 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>600 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.4</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Reported as table 22 in the FDA medical review (page 51): Reviewers mean placebo‐corrected change from baseline in BP by dose and age based on 5 placebo controlled studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007066-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reported as table 23 in the FDA medical review (page 52): Reviewers mean placebo‐corrected change from baseline in BP by dose and race based on 5 placebo controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>White</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Black</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Asian</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SBP mmHg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>DBP mmHg</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>150 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>300 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>600 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9.4</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Reported as table 23 in the FDA medical review (page 52): Reviewers mean placebo‐corrected change from baseline in BP by dose and race based on 5 placebo controlled studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007066-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparing MSSBP and MSDBP effect size of previous review versus present update after obtaining information from Clinical study Reports</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Dose of Aliskiren mg/day</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Previous version without access to information from CSR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Present version with access to information from CSR</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSSBP mmHg</b> </p> <p><b>MD with 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSDBP mmHg</b> </p> <p><b>MD with 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSSBP mmHg</b> </p> <p><b>MD with 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MSDBP mmHg</b> </p> <p><b>MD with 95% CI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aliskiren 75 mg vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.64 (‐4.06 to ‐1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.07 (‐2.94 to ‐1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.97 (‐4.76 to ‐1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.05 (‐3.13 to ‐0.96)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aliskiren 150 mg vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.55 (‐6.39 to ‐4.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.91 (‐3.46 to ‐2.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.95 (‐6.85 to ‐5.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.16 (‐3.74 to ‐2.58)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aliskiren 300 mg vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.93 (‐8.77 to ‐7.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.76 (‐5.33 to ‐4.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.88 (‐8.94 to ‐6.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.49 (‐5.17 to ‐3.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aliskiren 600 mg vs. Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.36 (‐13.53 to ‐9.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.57 (‐7.92 to ‐5.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐11.35 (‐14.43 to ‐8.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.86 (‐7.73 to ‐3.99)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>MSSBP:</b> mean sitting systolic blood pressure; <b>MSDBP:</b> mean sitting diastolic blood pressure; </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparing MSSBP and MSDBP effect size of previous review versus present update after obtaining information from Clinical study Reports</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007066-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study identifier(s) in various websites of individual studies meeting the inclusion criteria</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Novartis Clinical Trial Results Database identifier</b> </p> <p><b>used for study identification</b> </p> <p><b>in this review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Journal‐Published</b> </p> <p><b>Author /year</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Registered on</b> </p> <p><b>Novartis Clinical Trial</b> </p> <p><b>Results Database</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Registered on</b> </p> <p><b>ClinicalTrials.gov</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CSR* received from EMA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Request to</b> </p> <p><b>EMA was made on</b> </p> <p><b>November 15th 2015.</b> </p> <p><b>Weeks waited</b> </p> <p><b>to obtain CSR</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No journal publication</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT01237223</p> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EMA does NOT possess</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0076" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. ">Littlejohn 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00739973</p> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EMA does NOT possess</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0074" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. ">Kushiro 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT registered</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mar 11, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No journal publication</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00344110</p> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>May 23, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0060" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. ">Gradman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT registered</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jan 25, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0084" title="PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">Pool 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT FOUND</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT registered</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apr 12, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0094" title="VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">Villamil 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00219024</p> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apr 6, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0082" title="OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">Oh 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00219128</p> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feb 20, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0089" title="SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">Schmieder 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00219154</p> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>May 27, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0083" title="OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">Oparil 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results NOT posted</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT registered</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>June 16, 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0087" title="PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">Puig 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOT registered</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EMA does NOT possess</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0093" title="VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">Villa 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NCT00706134</p> <p>Results posted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>December 22, 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study identifier(s) in various websites of individual studies meeting the inclusion criteria</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007066-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparing MSSBP and MSDBP reduction between aliskiren doses from the same study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SBP WMD with 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>DBP WMD with 95% CI</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aliskiren 150 mg vs 75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.89 (‐3.16 to ‐0.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.80 (‐1.58 to ‐0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A<b>liskiren</b> 150 mg reduces SBP and DBP more than </p> <p>75 mg by 2/1 mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aliskiren 300 mg vs 75 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.10 (‐6.79 to ‐3.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.49 (‐3.53 to ‐1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A<b>liskiren</b> 300 mg reduces SBP and DBP more than </p> <p>75 mg 5/3 mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aliskiren 300 mg vs 150 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.62 (‐3.38 to ‐1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.80 (‐2.28 to ‐1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A<b>liskiren</b> 300 mg reduces SBP and DBP more than </p> <p>150 mg 3/2 mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aliskiren 600 mg vs 150 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.40 (‐5.58 to ‐1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐2.20 (‐3.55 to ‐0.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A<b>liskiren</b> 600 mg reduces SBP and DBP more than </p> <p>150 mg by 3/2mmHg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Aliskiren 600 mg vs 300 mg</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.61 (‐2.78 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐0.68 (‐2.03 to 0.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference was observed</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparing MSSBP and MSDBP reduction between aliskiren doses from the same study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007066-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Mortality during single‐blind, double‐blind and withdrawal period in the 12 included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study identifier</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Single‐blind period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Double‐blind period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal period</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death in placebo group during observation period due to pancreatic carcinoma and metastases to liver. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death occurred in aliskiren 150 mg monotherapy on day 41 of the study, due to drug intoxication. The overdose was attributed to a psychiatric drug prescribed prior to start of the study, and a diagnosis of manic depressive psychosis was recorded. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death occurred in the placebo arm on day 16 from "natural causes".</p> <p>One death occurred in the valsartan 160 mg arm (day 26) as a result of motor vehicle accident. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death was reported in the Aliskiren/HCTZ 150/25 mg group due to thoracic trauma from a motor vehicle accident. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 death occurred in placebo run‐in phase. Patient hospitalized due to supraventricular tachycardia and abdominal pain and died due to stroke after discontinuing from the study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death occurred in the aliskiren/HCTZ 150/300 mg group from acute bronchopneumonia and associated sepsis during the 30‐day follow‐up period after discontinuing the study. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 deaths reported.</p> <p>1 death in aliskiren group on day 41 due to myocardial infarction.</p> <p>1 death in valsartan group on day 13 and the cause was reported as hypertensive arteriosclerotic cardiovascular disease with SAE of sudden death. </p> <p>There were no deaths in placebo arm or combination therapy group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No deaths</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405:</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One death occurred during the follow‐up period of the study from pneumonia leading to respiratory failure (day of death not provided). Further information regarding this death is described in the patient narratives of the CSR, which we do not have access to yet. Within the CSR body, the arm of the study that this participant belongs to has been redacted. </p> <p>In the 2008 FDA Medical Review report, a death due to colon cancer is reported as occurring within <a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> (N = 1, aliskiren 300 mg). The medical review states "no other details were provided". For our comments on this please see <a href="#CD007066-sec-0100">Discussion</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><b>CSR:</b> clinical study report; <b>HTCZ:</b> hydrochlorothiazide; <b>SAE:</b> serious adverse event </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Mortality during single‐blind, double‐blind and withdrawal period in the 12 included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007066-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Non‐fatal serious adverse events during wash out, single‐blind, double‐blind and withdrawal period</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study identifier</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Wash out period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Single blind period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Double blind period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Withdrawal period</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No SAEs were reported in the aliskiren monotherapy group.</p> <p>2 in amlodipine 2.5 mg; 1 in amlodipine 5 mg; and 1 in aliskiren 150/amlodipine 5 mg combination arm (detail regarding SAE was not reported) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 SAEs reported.</p> <p>2 in placebo and 7 in other treatment groups (retinal detachment, abdominal mass, bronchitis, calculus ureteric, gastroenteritis, hand fracture, hydronephrosis, pneumonia, and cerebrovascular accident). </p> <p>None occurred in aliskiren 150 mg or 300 mg groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported 1 SAE in the single‐blind period ‐ infectious enterocolitis/dehydration (N = 1, 55M, placebo). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 SAEs in the double‐blind period:</p> <p>cerebral infarction (N = 1, 69F, placebo);</p> <p>acute myocardial infarction (N = 1, 58F, aliskiren 75 mg).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 SAEs reported.</p> <p>1 SAE in placebo due to myocardial infarction.</p> <p>The other in the losartan 50 mg group due to right medullary infarction.</p> <p>None in aliskiren 150 mg group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One in washout period ‐ transient Ischaemic attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two in the single‐blind run‐in phase ‐ anxiety; and diverticulitis and</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 SAEs in irbesartan group ‐ Intravertebral disc protrusion; and bipolar depression.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two in the withdrawal period in placebo group ‐ Left ventricular failure; and gout and infective arthritis). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported 6 SAE.</p> <p>1 bile duct cancer, 1 diverticulitis, 1 pregnancy, 1 mild melanorrhagia and gastric pain, 1 myocardial infarction, and 1 squamous cell carcinoma. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 SAEs reported.</p> <p>2 in Placebo: 1 due to natural cause and 1 due to myocardial infarction requiring hospitalization on day 46 resulting in study drug discontinuation. </p> <p>1 in aliskiren 75 mg on day 4 coronary artery disease requiring hospitalization resulting in study discontinuation. Patient required quadruple bypass surgery. </p> <p>1 in aliskiren 300 mg on day 42 pregnancy resulting in study discontinuation.</p> <p>1 in valsartan 160 mg on day 28 ‐ angioneurotic oedema resulting in study discontinuation, dyspnoea and chest pressure. </p> <p>Aliskiren 150 mg/valsartan 160 mg (N = 1, Day 29) motor vehicle accident requiring hospitalization; not discontinued from study. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 in aliskiren 75 mg/valsartan 80 mg on day 3 post‐study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 SAE due to (lung cancer, fractured leg, angina and urinary tract infection)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 patients experienced at least 1 SAE in the monotherapy and combination therapy treatment groups. </p> <p>1 in A 75 mg ‐ due to renal colic; 1 in aliskiren 150 mg due to haemorrhagic diarrhoea; none in aliskiren 300 mg; 1 in HCTZ 6.25 mg due to neoplasm of skin; 3 in HCTZ 12.5 mg ‐ due to breast cancer, joint injury and pregnancy; 2 in HCTZ 25 mg due to deep vein thrombosis and lymphadenopathy; 5 in aliskiren 75 mg/HCTZ 12.5 mg due to (diplopia, IIIrd nerve paresis, mood disorder, phlebothrombosis, psychotic disorder, small intestinal obstruction and syncope); 4 in aliskiren 75 mg/HCTZ 25 mg due to (cerebral infarction, dysarthria, physical disability, pregnancy and renal colic); 2 in aliskiren 150 mg/ HCTZ 6.25 mg ulcerative colitis, pregnancy); 3 in aliskiren 150 mg/ HCTZ 12.5 mg (non‐cardiac chest pain, pregnancy, syncope); 2 in aliskiren 150 mg/ HCTZ 25 mg (lung neoplasm, road traffic accident); 2 in aliskiren 300 mg/ HCTZ 12.5 mg (diabetes mellitus, lung disorder); 1 in aliskiren 300 mg/HCTZ 25 mg (coronary artery disease). </p> <p>There were no SAEs in the placebo group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 SAEs reported during washout period ‐ 1 due to subarachnoid haemorrhage due to rupture of cerebral aneurysm on day 8; </p> <p>1 due to partial small bowel obstruction on day 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One SAE ‐ bladder carcinoma prior to randomization and before receiving double‐blind study drug. Patient was randomized to placebo but later discontinued due to unsatisfactory therapeutic effect; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 SAEs reported.</p> <p>1 SAE in aliskiren 150 mg on day 27‐ unstable angina and increased blood pressure;</p> <p>2 SAEs in aliskiren 300 mg ‐ hospitalization for acute appendicitis on day 34; hospitalization for depression on day 51; </p> <p>1 SAE in aliskiren 600 mg of hospitalization for pain/bodily injury on day 35.</p> <p>No SAE reported in the placebo group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One SAE was reported during withdrawal period in aliskiren 150 mg of serious venous occlusion and thrombosis of the right eye on day 8 withdrawal period). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> </p> <p>data at week 3 and week 6 not available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>During 26 weeks double‐blind treatment period</p> <p>19 SAEs reported. 10 in aliskiren group and 9 in HCTZ group.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 SAEs reported.</p> <p>5 in placebo group ‐ atrial flutter, cerebrovascular accident, headache, hypertension, hypertensive crisis and ventricular tachycardia); </p> <p>8 in aliskiren group ‐ 1 gastritis, 1 grand mal convulsions, 1 intestinal poly, 2 myocardial infarction, 1 non‐cardiac chest pain, 1 peripheral vascular disease, 1 acute renal failure); </p> <p>6 in valsartan group ‐ 1 angina pectoris, 1 arteriosclerosis, 1 breast cancer, 1 bronchitis, 1 COPD, 1 facial paresis, 1 ovarian cancer, 1 pneumonia, 1 pulmonary oedema); </p> <p>3 in aliskiren/valsartan group ‐ 1 aortic aneurysm, 1 intravertebral disc protrusion, 1 prostate cancer and 1 thyroidectomy). </p> <p>The FDA medical review (2007) also reported two cases of renal carcinoma occurred (N = 1, placebo, day 20 post‐study; N = 1, aliskiren, day 44 post‐study). For our comments on this, please see <a href="#CD007066-sec-0100">Discussion</a>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 patients had serious AEs during the washout and placebo run‐in periods (detail of which are not provided). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 SAE was reported in aliskiren 75 mg group ‐ cardiac chest pain;</p> <p>2 in aliskiren 150 mg group ‐ rectal bleeding due to anal ulcer and episode of secondary anaemia; basal cell carcinoma; </p> <p>1 in the 300 mg group ‐TIA with concomitant nausea and dyspnoea; and</p> <p>2 in the placebo group ‐ prostate cancer; accelerated hypertension with left facial numbness. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405:</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported 2 SAEs in the washout period; Detail not provided in CSR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Three in the single‐blind placebo run‐in period. Detail not provided in CSR.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 SAEs were reported.</p> <p>2 in aliskiren 75 mg group ‐ erysipelas (skin infection) and osteoarthritis;</p> <p>3 in aliskiren 150 mg group ‐ severe glaucoma; moderate haemorrhoids; and mild hemorrhagic stroke; </p> <p>none in aliskiren 300 mg group; and</p> <p>1 in the placebo group ‐ vertigo, wrist fracture, concussion, and head contusion subsequent to a fall. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>COPD:</b> chronic obstructive pulmonary disease; <b>CSR:</b> clinical study report; <b>HTCZ:</b> hydrochlorothiazide; <b>SAE:</b> serious adverse event; <b>TIA:</b> transient ischaemic attack </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Non‐fatal serious adverse events during wash out, single‐blind, double‐blind and withdrawal period</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007066-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Total adverse events during double blind treatment period</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study Identifier</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs and Common AEs as reported in the corresponding available CSR</b> </p> <p><b>A = Aliskiren; P = Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A150 =15(7.8%); A 300 = 18(8.9%) and P = 22(7.7%) </p> <p><b>Headache:</b> A150 =13( 6.7%); A 300 =15(7.4%) and P = 20(10.1%) </p> <p><b>Periphaeral edema:</b> A150 = 2(1.0%); A 300 = 3(1.5%) and P = 2(1%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A150 = 40.1%; A 300 = 46.7%; A 600 = 52.4%; P = 43% </p> <p><b>Headache</b>: A150 = 12(7%); A300 = 13(7.7%); A600 = 9(5.4%); P = 16(9.7%) </p> <p><b>Nasopharyngitis</b>: A 150 = 5(2.9%); A 300 = 6(3.6%); A 600 = 3(1.8%); P = 10(6.1%) </p> <p><b>Dizziness</b>: A 150 = 2(1.2%); A 300 = 9(5.3%); A 600 = 5(3%); P = 7(4.2%) </p> <p><b>Diarrhoea</b>:A 150 = 2(1.2%); A 300 = 3(1.8%); A 600 = 19 (11.4%); P = 2(1.2%) </p> <p><b>Nausea</b>: A 150 = 2(1.2%); A 300 = 3(1.8%); A 600 = 0%; P = 4(2.4%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A75 = 61(53%); A150 = 58(51.8%); A 300 = 62(54.9%); P = 58(50.4)% </p> <p><b>Headache:</b> A75 = 3(2.6%); A 150 = 3(2.7%); A 300 = 6 (5.3%) and P = 4(3.5%) </p> <p><b>Nasopharyngitis</b>:A75 = 24(20.9%); A150 = 20(17.9%); A300 = 20(17.7%); P = 16(13.9%) </p> <p><b>Back pain</b>:A75 = 2(1.7%); A150 = 0%; A300 = 0% and P = 0% </p> <p><b>Diarrhoea:</b> A75 = 1(0.9%); A150 = 1(0.9%); A300 = 4(3.5%) and P = 1(0.9%) </p> <p><b>Vertigo:</b> A75 =0%; A150 = 0%); A300 = 1(0.9%) and P = 2(1.7%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs:</b> A150 = 152(50.3%), P = 66(42.3%) </p> <p><b>Nasopharyngitis:</b> A150 = 48(15.9%), P = 13(8.3%) </p> <p><b>Headache:</b> A150 = 9(3.0%), P = 6(3.8%) </p> <p><b>Occult blood positive:</b> A150 = 9 (3.0%), P =5 (3.2%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs:</b> A150 = 127 (26.8%); A300 = 130 (36.2%); A600 = 43 (33.1%); P = 32 (32.1%) </p> <p><b>Headache:</b> A150 = 3 (2.4%); A300 = 8 (6.2%); A600 = 6 (4.6%); P = 7 (5.3%) </p> <p><b>Diarrhoea:</b> A150 = 2 (1.6%); A300 = 1 (0.8%); A600 = 9 (6.9%); P = 2 (1.5%) </p> <p><b>Dizziness:</b> A150 = 2 (1.6%); A300 = 4 (3.1%); A600 = 3 (2.3%); P = 5 (3.8%) </p> <p><b>Fatigue:</b> A150 = 1 (0.8%); A300 = 5 (3.8%); A600 = 2 (1.5%); P = 4 (3.1%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A75 = 63(35.2%); A150 = 59(33.1%); A300 = 50(28.6%) and P = 57(32.2%) </p> <p><b>Headache</b>: A75 = 15(8.4%); A150 = 9(5.1%;) A 300 = 7(4.0%) and P = 15(8.5%) </p> <p><b>Fatigue</b>: A75 = 7(3.9%); A150 = 4(2.2%;) A 300 = 4(2.3%) and P = 4(2.3%) </p> <p><b>Back pai</b>n: A75 = 2(1.1%); A150 = 4(202%;) A 300 = 3(1.7%) and P = 2(1.1%) </p> <p><b>Diarrhoea</b>: A75 = 2(1.1%); A150 = 1(0.6%;) A 300 = 5(2.9%) and P = 3(1.7%) </p> <p><b>Dizziness:</b> A75 = 4(2.2%); A150 = 4(2.2%;) A 300 = 3(1.7%) and P = 2(1.1%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs:</b> A75 = 69(37.5%); A150 = 69(37.3%); A300 = 71 (39.2%); P = 85(44%) </p> <p><b>Headache</b>: A75 = 13(7.1%); A 150 = 13(7%); A 300 = 10 (5.5%); P = 26 (13.5%) </p> <p><b>Nasopharyngitis:</b> A75 = 9( 4.9%); A150 = 5(2.7%;) A300 = 3 (1.7%); P = 10 (5.2%) </p> <p><b>Diarrhoea</b>: A75 = 3(1.6%); A150 = 3(1.6%); A300 = 4(2.2%); P = 1(0.5%) </p> <p><b>Cough</b>: A75 = 1(0.5%); A150 = 2(1.1%); A300 = 1(0.6%); P = 1(0.5%) </p> <p><b>Dizziness</b>: A75 = 1(0.5%); A150 = 1(0.5%); A300 = 3(1.7%); P = 2(1.0%) </p> <p><b>Peripheral edema:</b> A75 = 4(2.2%); A150 = 3(1.6%); A300 = 2(1.1%); P = 1(0.5%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A150 = 40.1%; A 300 = 46.7%; A 600 = 52.4%; P = 43% </p> <p><b>Headache</b>: A150 = 12(7%); A300 = 13(7.7%); A600 = 9(5.4%); P = 16(9.7%) </p> <p><b>Nasopharyngitis</b>: A 150 = 5(2.9%); A 300 = 6(3.6%); A 600 = 3(1.8%); P = 10(6.1%) </p> <p><b>Dizziness</b>: A 150 = 2(1.2%); A 300 = 9(5.3%); A 600 = 5(3%); P = 7(4.2%) </p> <p><b>Diarrhoea</b>: A 150 = 2(1.2%); A 300 = 3(1.8%); A 600 = 19 (11.4%); P = 2(1.2%) </p> <p><b>Nausea</b>: A 150 =2 (1.2%); A 300 = 3(1.8%); A 600 =0%; P = 4(2.4%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b> at 6 weeks : A 26.4%; P = 28.5% (numbers not reported) </p> <p><b>Other AE</b> were not reported at week 6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs:</b> A150 to 300 = 149(34%) and P = 168(37%) </p> <p><b>Headach</b>e: A150 to 300 = 14(3.2%); P = 41(9%) </p> <p><b>Diarrhoea*</b>: A150 to 300 = 2.3%; P = not reported </p> <p><b>Nasopharyngitis</b>: A150 to 300 = 16(3.7%) ; P = 9(2%) </p> <p><b>Dizziness:</b> A 150 to 300 = 8(1.8%) ; P = 9(2%) </p> <p><b>Fatigue</b>:A 150 to 300 = 4(0.9%) ; P = 5(1.1%) </p> <p><b>Nausea</b>: A 150 to 300 = 6(1.4%) ; P = 11(2.4%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs:</b> A75 = 57(37.3%); A150 = 59(34.7%); A300 = 56(35.4%); P = 60(37.5%) </p> <p><b>Headache:</b> A75 = 12(7.8%); A150 = 7(4.1%); A300 = 10(6.3%) and P = 9(5.6%) </p> <p><b>Nasopharyngitis</b>: A75 = 2(1.3%); A150 = 2(1.2%); A300 = 5(3.2%) and P = 3(1.9%) </p> <p><b>Diarrhoea</b>: A75 = 7(4.6%); A150 = 2(1.2%); A300 = 1(0.6%) and P = 1(0.6%) </p> <p><b>Cough</b>: A75 = 1(0.7%); A150 = 4(2.4%); A300 = 1(0.6%) and P = 3(1.9%) </p> <p><b>Dizziness</b>: A75 = 1(0.7%); A150 = 5(2.9%); A300 = 1(0.6%) and P = 3(1.9%) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405:</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total AEs</b>: A75 = 36(18.8%); A150 = 41(21.7%); A300 = 36(19.1%); P = 39(21.0%) </p> <p><b>Headache</b>: A75 = 4(2.1%);A150 = 2(1.1%); A300 = 1(1.1%); P = 4(2.1%) </p> <p><b>Influenza:</b> A75 = 1(0.5%); A150 = 4(2.1%); A300 = 1(1.1%); P = 1(0.5%) </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Total adverse events during double blind treatment period</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007066-tbl-0011"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Listing reasons for withdrawal due to adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study Identifier</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reasons for increased withdrawal due to adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0001" title="Novartis . Efficacy and safety of SPA100 (fixed‐dose combination of aliskiren/amlodipine) in patients with essential hypertension. ClinicalTrials.gov identifier NCT01237223 May 11 2012:1‐27. ">CSPA100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0002" title="LittlejohnTW3rd , JonesSW , ZhangJ , HsuH , KeefeDL . Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double‐blind, multifactorial study. Journal of Human Hypertension2013;27(5):321‐7. Novartis . An 8‐week double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with amlodipine in patients with essential hypertension. Novartis Clinical Trial Results Database. 26th May 2010:1‐16. [Little John] ">CSPA100A2305</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0003" title="KushiroT , HiroshigeI , YoshihisaA , HiromiG , ShinjiT , KeefeD . Aliskiren, a novel oral renin inhibitor, provides dose‐dependent efficacy and placebo‐like tolerability in Japanese patients with hypertension. Hypertension Research ‐ Clinical &amp; Experimental2006;29(12):997‐1005. Novartis . Dose‐finding study of SPP100 in essential hypertension. Clinical Study Report. European Medicines Agency October 13th 2005:10531‐665. ">CSPP100A1201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant adverse events occurred for N = 7 patients, leading to discontinuation from study, as described below. </p> <p> <ul id="CD007066-list-0011"> <li> <p>Placebo (N = 3): moderately elevated blood pressure (N = 1); moderate rotary vertigo and moderately elevated blood pressure (N = 1); cerebral infarction (N = 1); aliskiren 75 mg (N = 1): acute myocardial infarction (N = 1). </p> </li> <li> <p>Aliskiren 150 mg (N = 1): moderately elevated blood pressure (N = 1); aliskiren 300m g (N = 2); moderately elevated blood pressure (N = 1; drug eruption (N = 1). Adverse events suspected to be study drug‐related occurred in N = 5 patients. These events improved or resolved upon discontinuation of study drug. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0004" title="Novartis . A randomized, double‐blind, placebo and active‐controlled, multicenter, parallel‐group study comparing SPP100 (Aliskiren) 150 mg to placebo and to Losartan 50 mg to evaluate efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension. Clinical Study Report. European Medicines Agency January 10, 2008:1‐137. ">CSPP100A1301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD007066-list-0012"> <li> <p>Placebo = 7(4.5%): blood pressure increased (N = 3, 1.9%); headache (N =1, 0.6%); SBP increased (N = 1, 0.6%); gastroenteritis (N = 1, 0.6%); myocardial infarction (N = 1, 0.6%). Also, 6 (3.8%) patients withdrew due to abnormal test procedure results. </p> </li> <li> <p>Aliskiren 150 mg = 5 (1.7%); 5 (1.7%): joint pain (N =1, 0.3%); blood pressure increased (N =1, 0.3%); dizziness (N =1, 0.3%); head discomfort (N =1, 0.3%); headache (N = 1, 0.3%); and nausea (N =1, 0.3%). Also 5(1.7%) patients withdrew due to abnormal test procedure results. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0005" title="GradmanA , SchmiederR , LinsR , NussbergerJ , ChiangY , BedigianM . Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation2005;111:1012‐8. Novartis . A multicentre, randomized, double blind, placebo‐controlled, parallel‐group study comparing aliskiren 150 mg, 300 mg, and 600 mg and Irbesartan 150 mg in patients with mild‐to‐moderate essential hypertension. Clinical Study Report. European Medicines Agency April 1st 2004:1‐61. NussbergerJ , GradmanAH , SchmiederRE , LinsRL , ChiangY , PrescottMF . Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. International Journal of Clinical Practice2007;61(9):1461‐1468. ">CSPP100A2201</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A total of N = 18 patients discontinued from the study due to AEs. It was suspected that 2/3 of these discontinuations were for reasons drug‐related. Headaches resulted in the discontinuation for N = 3 patients. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0006" title="Novartis . A randomized, double blind, multicentre, multifactorial, placebo‐controlled, parallel‐group study to confirm the efficacy and safety of aliskiren monotherapy, and evaluate efficacy and safety of combinations of aliskiren and valsartan in hypertensive patients. Clinical Study Report. European Medicines Agency June 8th 2005:1547‐1634. PoolJ , RolandE , SchmiederM , AldigierJC , JanuszewiczA , ZidekW , ChiangY , SatlinA . Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. American Journal of Hypertension2007;20(1):11‐20. ">CSPP100A2203</a>; </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most frequent reasons for 12 discontinuations are: fatigue (N = 5, 0.4%), headache (N = 3, 0.3%), diarrhoea (N = 2, 0.2%), and peripheral oedema (N = 2, 0.2%). </p> <p>Reasons for 14 discontinuations from AE (safety population).</p> <p> <ul id="CD007066-list-0013"> <li> <p>Placebo (N = 6, 3.4): myocardial infarction (N = 1, 0.6%); tachycardia (N = 1, 0.6%); diarrhoea (N = 1, 0.6%); fatigue (N = 1; 0.6%), peripheral oedema (N = 1, 0.6%); sudden death (N = 1, 0.6%); headache (N = 1, 0.6%). </p> </li> <li> <p>Aliskiren 75 mg (N = 5): coronary artery disease (N = 1, 0.6%); abdominal pain (N = 1, 0.6%); diarrhoea (N = 1, 0.6%); oedema (N = 1, 0.6%); headache (N = 1, 0.6%); syncope (N = 1, 0.6%); dermatitis bullous (N = 1, 0.6%); eczema (N = 1, 0.6%). </p> </li> <li> <p>Aliskiren 150 mg (N = 3, 1.7%): fatigue (N = 1, 0.6%); blood creatine phosphokinase increased (N = 1, 0.6%); pulse pressure increased (N = 1, 0.6%); migraine (N = 1, 0.6%); cold sweat (N = 1, 0.6%). </p> </li> </ul> </p> <p>The FDA medical review reports facial oedema (N = 1, 0.6%) that appears to be angioedema, resulting in discontinuation from study; however, this is not reported in CSR 2203. </p> <p> <ul id="CD007066-list-0014"> <li> <p>Aliskiren 300 mg (N = 3, 1.7%): vertigo (N = 1, 0.6%); influenza‐like illness (N = 1, 0.6%); flank pain (N = 1, 0.6%); pregnancy (N = 1, 0.6%). </p> </li> <li> <p>Additionally, in the aliskiren 150 mg arm, discontinuation from study occurred for (N = 1, 0.6%) abnormal laboratory values. </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0007" title="Novartis . An 8 week, double‐blind, multicenter, randomized, multifactorial, placebo‐controlled, parallel group,study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hydrochlorothiazide in patients with essential hypertension. Clinical Study Report. European Medicines Agency October 25th 2005:3354‐3454. VillamilA , ChrysantS , CalhounD , SchoberB , HsuH , Matrisciano‐DimichinoL , ZhangJ . Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. Journal of hypertension2007;25(1):217‐226. ">CSPP100A2204</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The range of AEs resulting in study discontinuation is 0% is the aliskiren 150 mg arm of the study to 4.4% in the aliskiren 300 mg arm (N = 7). The most frequent AE resulting in study discontinuation is headache (N = 12, 0.4%). </p> <p>Reasons for discontinuations from adverse events ‐ N = 62 (2.2%).</p> <p> <ul id="CD007066-list-0015"> <li> <p>Placebo (N = 7, 3.6%): blood pressure increased (N = 1, 0.5%; depression (N = 1, 0.5%); dizziness (N = 1, 0.5%); eye pruritis (N = 1, 0.5%); gastritis (N = 1, 0.5%); insomnia (N = 1, 0.5%): lacrimation increased (N = 1, 0.5%); tinnitus (N = 1, 0.5%). </p> </li> <li> <p>Aliskiren 75 mg (N = 1, 0.5%): dizziness (N = 1, 0.5%); nausea (N = 1, 0.5%).</p> </li> <li> <p>Aliskiren 150 mg (N = 0).</p> </li> <li> <p>Aliskiren 300 mg (N = 8, 4.4%): angina pectoris (N = 1, 0.6%); asthenia (N = 2, 1.1%); cough (N = 1, 0.6%); dizziness (N = 1, 0.6%); peripheral oedema (N = 1, 0.6%); emotional disorder (N = 1, 0.6%); fatigue (N = 1, 0.6%); headache (N = 1, 0.6%). </p> </li> </ul> </p> <p>Additionally four patients discontinued from the study due to abnormal laboratory values. </p> <p> <ul id="CD007066-list-0016"> <li> <p>Placebo (N = 1,Day 43): asymptomatic low white blood cell count.</p> </li> <li> <p>Aliskiren 75 mg (N = 1, Day 15): abnormal ranges found for haematology and chemistry parameters. </p> </li> <li> <p>Aliskiren 150 mg (N = 1, Day 6): elevated cholesterol and liver enzymes.</p> </li> <li> <p>Aliskiren/HCTZ 150 25 mg/25 mg (N=1, Day 9): elevated cholesterol, BUN, uric acid.</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Most frequent reasons for 9 discontinuation from study: headache (N = 4), dizziness (N = 3), and diarrhoea (N = 2). </p> <p>Reasons for discontinuations from AE (safety population).</p> <p> <ul id="CD007066-list-0017"> <li> <p>Headache (placebo: N = 4); dizziness (placebo; N = 2; aliskiren 300 mg; 1), diarrhoea (placebo: N = 1; aliskiren 600 mg: N = 1); increased blood pressure (1 in placebo group); duodenal ulcer (placebo: N = 1); hypotension (placebo: N = 1); lethargy (placebo: N = 1); muscle spasm (placebo: N = 1); nausea (placebo: N = 1); and urticaria (placebo: N = 1); flatulence (aliskiren 600 mg: N = 1); altered mood (aliskiren 300 mg: N = 1); rash (aliskiren 300 mg: N = 1); and sense of oppression (aliskiren 150 mg: N = 1). </p> </li> <li> <p>No patients were discontinued for abnormal laboratory values.</p> </li> </ul> </p> <p>We question that a participant withdrew for the reason specified as "unsatisfactory effect" as opposed to being categorized as a discontinuation from an SAE as the event necessitated hospitalization. On Day 27 in <a href="./references#CD007066-bbs2-0008" title="Novartis . An 8 week, randomized, double‐blind, placebo‐controlled, parallel group, multicenter, study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines Agency November 1st 2005:8458‐543. OhB , MitchellJ , HerronJ , ChungJ , KhanMl , KeefeD . Aliskiren, an oral renin inhibitor, provides dose‐dependent efficacy and sustained 24‐hour blood pressure control in patients with hypertension. Journal of the Amarican College of Cardiology2007;49(11):1157‐63. ">CSPP100A2308</a>, the participant (N = 1, 64F, aliskiren 150 mg) was hospitalized for unstable angina and increased blood pressure. The unstable angina was treated with concomitant medication and her condition resolved within 3 days. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0009" title="Novartis . A twenty six‐week, randomized, double‐blind, parallel group, multicenter, active‐controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional addition of amlodipine, followed by a second twenty six weeks of blinded treatment, in patients with essential hypertension. Clinical Study Report. European Medicines Agency May 16th 2006:28012‐9161. SchmiederRE , PhilippT , GuerediagaJ , GorostidiM , SmithB , WeissbachN , et.al . Long‐term antihypertensive efficacy and safety of the Oral direct renin Inhibitor aliskiren. Circulation2009;119:417‐25. ">CSPP100A2323</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We do not have data at week 3 and week 6 for this study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0010" title="Novartis . An eight‐week randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing aliskiren 150 mg, 300 mg, and 600 mg to placebo in patients with essential hypertension. Clinical Study Report. European Medicines AgencySeptember 2006:17604‐20246. OparilS , YarrowsS , PatelSF , AngH , ZhangJ , SatlinA . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double‐blind trial. Lancet2007;370(9583):221‐9. ">CSPP100A2327</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The range of AEs resulting in study discontinuation is 8 (1.8%) is the aliskiren arm; 8 (2.6%) in valsartan arm; 6 (1.3%) in aliskiren/valsartan combination arm; and 11 (2.4%) in the placebo arm. </p> <p>Reasons for discontinuations from adverse events ‐ N = 37 (2%).</p> <p> <ul id="CD007066-list-0018"> <li> <p>Placebo (N = 11, 2.4%): headache (N = 4, 0.9%); nausea (N = 1, 0.2%); dyspnoea (N = 1, 0.2%); atrial flutter (N = 1, 0.2%); dizziness (N = 1, 0.2%); epistaxis (N = 1, 0.2%): hypertension (N = 1, 0.2%); hypertensive crisis (N = 1, 0.2%); peripheral oedema (N = 1, 0.2%). </p> </li> </ul> <ul id="CD007066-list-0019"> <li> <p>Aliskiren = 8 (1.8%): blood pressure increased (N =1, 0.2%); gastritis (N =1, 0.2%); grand mal convulsion (N = 1, 0.2%); headache (N = 1, 0.2%); myocardial infarction (N = 2, 0.5%); non‐cardiac chest pain (N = 2, 0.5%); acute renal failure (N = 1, 0.2%). </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0011" title="Novartis . A randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study comparing an eight‐week treatment of aliskiren 75 mg, 150 mg and 300 mg to placebo in patients with essential hypertension. Novartis Clinical Trials Results Database November 4th 2009:1‐14. PuigJG , SchunkertH , TaylorAA , BoyeS , JinJ , KeefeDL . Evaluation of the dose‐response relationship of aliskiren, a direct renin inhibitor in an 8‐week, multicenter, randomized, double‐blind, parallel‐group, placebo‐controlled study in adult patients with stage 1 or 2 essential hypertension. Clinical Therapeutics2009;31(12):2839‐50. ">CSPP100A2328</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aliskiren 75 mg = 3 (2.0%); aliskiren 150 mg = 5 (2.9%); aliskiren 300 mg = 4(2.5%) . </p> <p>Placebo = 4 (2.5%). Reasons for withdrawal were not reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007066-bbs2-0012" title="Novartis . An eight‐week double‐blind, multi‐center, randomized, placebo‐controlled, parallel‐group study to evaluate the efficacy and safety of aliskiren 75 mg, 150 mg and 300 mg in elderly patients with essential hypertension when given with a light meal. Clinical Study Report. European Medicines Agency. Date not reported:1‐100. VillaG , LeBretonS , IbramG , KeefeD . Efficacy, safety and tolerability of Aliskiren monotherapy administered with a light meal in elderly hypertensive patients: A randomized, double blind, placebo‐controlled, dose‐response evaluation study. Journal of Clinical Pharmacology2012;52:1901‐11. ">CSPP100A2405:</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reasons for 18 discontinuations from AE (safety population)</p> <p> <ul id="CD007066-list-0020"> <li> <p>Placebo (N = 7, 3.8%): hypertension (N = 5, 2.7%); hypertensive crisis (N = 1, 0.5%); gastroenteritis (N = 1, 0.5%). </p> </li> <li> <p>Aliskiren 75 mg (N = 7, 3.7%): hypertension (N = 1, 0.5%); headache (N = 1, 0.5%); dizziness (N = 2, 1.0%); hypertensive crisis (N = 1, 0.5%); dyspepsia (N = 1, 0.5%); nausea (N = 1, 0.5%). </p> </li> <li> <p>Aliskiren 150 mg (N = 1); hypertension (N = 1).</p> </li> <li> <p>Aliskiren 300 mg (N = 3): hypertension (N = 2, 1.1%),;headache (N = 1, 0.5%); vertigo (N = 1, 0.5%) </p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Listing reasons for withdrawal due to adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/full#CD007066-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007066-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Aliskiren vs. placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aliskiren 75 mg vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.97 [‐4.76, ‐1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Aliskiren 150 mg vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.95 [‐6.85, ‐5.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Aliskiren 300 mg vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.88 [‐8.94, ‐6.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Aliskiren 600 mg vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.35 [‐14.43, ‐8.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Aliskiren 75 mg vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.05 [‐3.13, ‐0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Aliskiren 150 mg vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.16 [‐3.74, ‐2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Aliskiren 300 mg vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.49 [‐5.17, ‐3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Aliskiren 600 mg vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.86 [‐7.73, ‐3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawals due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 75 mg vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.33, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 150 mg vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.30, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 300 mg vs. placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.47, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 600 mg vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.19, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cough <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2886</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.49, 2.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Aliskiren 75 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.85, 5.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Aliskiren 150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.78, 3.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Aliskiren 300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [0.89, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Aliskiren 600 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [2.48, 19.72]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Aliskiren vs. placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007066-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Aliskiren150 mg vs. Aliskiren 75 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.89 [‐3.16, ‐0.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐1.58, ‐0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Aliskiren150 mg vs. Aliskiren 75 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007066-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Aliskiren 300 mg Vs. Aliskiren 75 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 SBP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.10 [‐6.79, ‐3.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 DBP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.49 [‐3.53, ‐1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Aliskiren 300 mg Vs. Aliskiren 75 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007066-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Aliskiren 300 mg vs. Aliskiren 150 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.62 [‐3.38, ‐1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐2.28, ‐1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Aliskiren 300 mg vs. Aliskiren 150 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007066-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Aliskiren 600 mg vs. Aliskiren 150 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 SBP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.40 [‐5.58, ‐1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 DBP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐3.55, ‐0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Aliskiren 600 mg vs. Aliskiren 150 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007066-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Aliskiren 600 mg vs. Aliskiren 300 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Systolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐2.78, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Diastolic BP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>592</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐2.03, 0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Aliskiren 600 mg vs. Aliskiren 300 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007066.pub3/references#CD007066-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007066.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007066-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007066-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD007066-note-0005">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD007066-note-0003">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007066-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD007066-note-0006">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007066-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007066-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007066\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007066\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007066\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007066\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007066\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007066.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007066.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007066.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007066.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007066.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715402470"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007066.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715402474"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007066.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8639dd339374',t:'MTc0MDcxNTQwMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 